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ABSTRACT 
 
HOSPITAL RESOURCE UTILIZATION AMONG PATIENTS WITH CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE – AN ANALYSIS OF 2002 – 2005 
HEALTHCARE COST AND UTILIZATION PROJECT DATA 
 
 
By 
Pallavi B. Rane 
May 2010 
 
Thesis supervised by: Dr. Khalid Kamal 
Objective: The objective of this study is to develop a national assessment of the length of 
stay (LOS), total costs, and in-hospital mortality among patients with chronic obstructive 
pulmonary disease (COPD), using retrospective data derived from Nationwide Inpatient 
Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP). 
Methods: COPD- related hospitalizations using inpatient discharge-level data derived 
from 2005 NIS was utilized.  Records with principal diagnosis of COPD were extracted 
using ICD-9 codes 490.xx-492.xx and 496.xx.  Patient- (age, race, gender, payer, patient 
location, and median household income) and hospital-related (region, location, hospital 
bed size, type of admission type, and number of procedures on record) variables were 
considered in the analysis.  Descriptive analysis was conducted to examine the 
differences in COPD-related hospital LOS, total hospital costs, and in-hospital mortality.  
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Multiple regression was conducted to identify predictors of LOS, costs, and in-hospital 
mortality among patients with COPD. 
Results: An estimated total of 616,818 hospitalized cases for COPD as primary 
diagnosis, and 1,426,723 cases for COPD as secondary diagnosis were identified. The 
study showed that the burden of disease associated with COPD is substantially 
underestimated, and that it usually affects females, Caucasians, people aged 65 and 
above, and people from lower income level groups.  It was also seen that COPD most 
commonly affected people located in the metropolitan areas, and also those from the 
southern region of the US. The mean LOS was found to be 4.69 and mean total costs 
were found to be $6,939.  An estimated 12,054 in-hospital deaths were observed with 
COPD listed as the primary diagnosis. The study clearly demonstrated that disparities do 
exist in occurrence of COPD, and the outcomes related to the disease. Number of 
procedures and number of diagnoses listed on the record; were seen to be important 
predictors for hospital LOS, total hospital costs as well as in-hospital mortality.  Hospital 
region, gender, and payer were among other important predictors for hospital LOS; 
whereas for total hospital costs, important predictors included hospital region, race, and 
patient location. Age and gender were seen to be important predictors of in-hospital 
mortality. For the years 2002-2005, a decreasing trend in hospital LOS was observed, 
while an increasing trend was observed for total hospital costs. 
Conclusion: Hospital resource utilization is high in patients with COPD.  Appropriate 
disease management, and application of preventative care such as early disease 
management for COPD, and the related co-morbidities in identified population, can help 
in lowering hospital admission rates and costs associated with it. 
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CHAPTER ONE 
INTRODUCTION 
 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 
formed by the United States (US) National Heart, Lung, and Blood Institute (NHLBI) 
and the World Health Organization (WHO), define Chronic Obstructive Pulmonary 
Disease (COPD) as a preventable and treatable disease with some significant 
extrapulmonary effects that may contribute to the disease severity in individual patients.  
COPD is an incessant disease characterized by decline in lung function and obstruction to 
air flow that is not fully reversible.1, 2  
The obstruction in the air flow is caused by a combination of obstructive 
bronchitis and emphysema.1, 2  In obstructive bronchitis, the chronic inflammation of the 
small airways leads to structural changes resulting in airflow limitation.  In emphysema, 
the inflammation causes destruction of the lung parenchyma.  The parenchymal 
destruction leads to loss of alveolar attachments to the small airways and decreases lung 
elastic recoil, which impairs the ability of the airways during expiration.  The relative 
contribution of obstructive bronchitis and/or emphysema, to the disease severity may 
vary from person to person.1  
An exacerbation of COPD is defined as an event in the natural course of the 
disease characterized by a change in the patient’s baseline dyspnea, cough, and/or sputum 
that is beyond normal day-to-day variations.  An exacerbation is acute in onset, and may 
warrant a change in regular medication in a patient with underlying COPD.1   Patients 
with COPD on an average, have two exacerbations per year.3  Exacerbations are the  main 
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cause of medical visits and hospitalizations, and they are associated with a high health-
care expenditure.4, 5  Exacerbations in COPD also have serious negative impact on 
patient’s quality of life, lung function , and socioeconomic costs.1 
 
Pathology, Pathogenesis, and Pathophysiology 
Typical characteristics of pathological changes in COPD include chronic 
inflammation with increased number of specific inflammatory cell types, and structural 
changes resulting from repeated injury and repair.  These changes occur in the proximal 
airways, peripheral airways, lung parenchyma, and pulmonary vasculature.  In patients 
with COPD, the inflammation appears to be an amplification of the normal response of 
the respiratory tract to chronic irritants such as cigarette smoke.  COPD involves a 
specific pattern of inflammation involving inflammatory cells like neutrophiles, 
macrophages and lymphocytes.  The inflammatory cells release inflammatory mediators 
like chemotactic factors, proinflammatory cytokinines, and growth factors; which interact 
with structural cells in the airways and lung parenchyma.  Lung inflammation is further 
amplified by oxidative stress or a protease-antiprotease imbalance.   
Physiological changes in COPD include mucus hypersecretion, airflow limitation 
and air trapping, gas exchange abnormalities, and cor pulmonale.  The several systemic 
features, especially in patients with severe COPD include cachexia, skeletal muscle 
wasting, increased risk of cardiovascular disease, anemia, osteoporosis, and depression.  
Exacerbations are a further amplification of the inflammatory responses in COPD, and 
may be triggered by infection with bacteria or viruses or by environmental pollutants.1 
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Epidemiology  
COPD is considered to be a major cause of morbidity and mortality across the 
world, and its prevalence continues to increase.6  Currently 12.1 million US adults (aged 
≥ 18 years) are estimated to have been diagnosed with COPD and as many as 24 million 
US adults have evidence of impaired lung function; indicating an under-diagnosis of 
COPD.7  COPD can be described as an ill-defined mixture of overlapping manifestations 
of chronic bronchitis, emphysema, and asthma.  And because of the overlapping 
symptoms associated with these conditions, COPD is often misdiagnosed or under 
diagnosed.8   Additionally, variable definitions, and different diagnostic criteria of COPD 
have significantly lead to the underestimation of COPD.  Study results have shown that 
the burden of disease associated with COPD is largely underestimated, as COPD is 
usually listed as a secondary diagnosis.9  It has been found that morbidity due to COPD 
increases with age and is greater in men than women.  The prevalence of COPD has also 
been found to be considerably higher in smokers and ex-smokers, and in individuals over 
40 years of age.1, 10   
COPD is the fourth leading cause of death in the US accounting for nearly 1.3 
million lives in 2003, and it has been predicted to become the third most common cause 
of mortality by 2020.7, 11   Trends in death rate in the US from 1970 through 2002 for the 
six leading causes of death indicate; that while mortality from several of these chronic 
conditions declined, mortality due to COPD increased during that period.2   The increase 
in mortality rate in females due to COPD is also alarming.  Between 1971 and 2000, a 
five-fold increase in mortality rate was observed among females.12  In 2003 alone, 63,000 
females died due to COPD as compared to 59,000 males.7  The  increased and changing  
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COPD mortality trend could be due to the expanding epidemic of smoking and the 
changing demographics.11 
 
Economic and Social Burden  
The economic and social burden associated with COPD is enormous.1, 4   COPD is 
a costly disease in terms of both direct and indirect costs.1  According to the NHLBI, 
annual cost of COPD (2007 value) in the US was around $42.6 billion.  This included 
$26.7 billion in direct health care expenditures, $8 billion in indirect morbidity costs, and 
$7.9 billion in indirect mortality costs.7  Hospitalization accounted for a major portion 
($11.3 billion) of the direct health care expenditure.  The total cost of care for patients is 
significantly increased due to presence of COPD, especially in terms of inpatient costs.  
The per capita expenditures for hospitalizations of COPD patients were found to be 2.7 
times the expenditures for patients without COPD.13  Also, a direct relationship exists 
between the severity of COPD and the cost of care.  It has been reported that 
hospitalization and ambulatory oxygen costs increase as the disease progresses.14  
The social burden of COPD is also increasing and in terms of Disability-Adjusted 
Life Years (DALYs) lost worldwide, COPD is expected to become the fifth leading cause 
in 2020; from being the twelfth leading cause among all chronic diseases in 1990.15    
 
Risk Factors  
A number of risk factors have been attributed to the development of COPD. 
Cigarette smoking is a major risk factor for COPD.1  It is widely believed that 15% of 
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smokers develop COPD, however according to the recent US National Health and 
Nutrition study (NHANES), sooner or later as many as 50% of the smokers may develop 
COPD.16  Environmental or occupational exposure to lung irritants due to air pollution 
from chemical fumes, vapors, and dusts; exposure to biomass smoke; early-life infections 
and malnutrition have also been identified as a COPD risk factors.1, 9  COPD is a 
progressive disease, particularly if the patient’s exposure to such noxious agents 
continue.1  The hereditary deficiency of alpha-1 antitrypsin, a rare recessive genetic trait 
most commonly seen in individuals of Northern European origin; is also reported as a 
risk factor for COPD.2 
 
COPD and Co‐morbidities  
COPD generally develops in middle aged population, with a long smoking 
history. And  co-morbid conditions related to either smoking or aging, either already exist 
in this population; or they are at an increased risk to develop such co-morbidities.17  The 
extrapulmonary effects related to COPD itself can lead to other co-morbid conditions.  
Some of the most common co-morbid conditions that have been described in association 
with COPD include pneumonia, hypertension, diabetes, coronary artery disease, heart 
failure, pulmonary infections, cancer, and pulmonary vascular disease.  Studies have also 
shown that co-morbidities in patients with COPD, especially cardiovascular diseases and 
lung cancer play an important role in increasing  the hospitalizations and  risk of 
mortality among patients with COPD.17  
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Disease Management  
The GOLD guidelines suggest that an effective COPD management plan includes 
four components - assess and monitor disease, reduce risk factors, manage stable COPD, 
and manage exacerbations.1 
Assessment and classification of COPD disease severity  
The impact of COPD on patients depends not only on the degree of airflow 
limitation but also on any existing co-morbidities, and the severity of disease symptoms.1  
The symptoms of COPD  include chronic and progressive dyspnea, breathlessness, and 
decreased exercise capacity, cough, and sputum production.2   The diagnosis of COPD, 
and determination of disease severity in COPD is usually done by the spirometry test.1  
Spirometry measures the volume of air forcibly exhaled from the point of maximal 
inspiration (forced vital capacity, FVC) and the volume of air exhaled during the first 
second of this maneuver (forced expiratory volume in one second, FEV1).  The ratio of 
these two measurements (FEV1/FVC) is calculated, and the presence of airflow limitation 
is defined by a post-bronchodilator FEV1/FVC < 0.70.  The GOLD guidelines use 
patient’s pulmonary function parameter such as post-bronchodilator FEV1, to classify 
patients into different disease severity group (see Table1).2 
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Table 1: Different stages of disease severity based on FEV1 value 
 
Stage                           Severity    FEV1 /FVC  
 
I   Mild COPD    FEV1 /FVC < 0.70 
FEV1 ≥ 80% predicted 
 
II   Moderate COPD   FEV1 /FVC < 0.70 
50% ≤ FEV1 < 80% predicted 
 
III   Severe COPD    FEV1 /FVC < 0.70 
            30% ≤ FEV1 < 50% predicted 
 
IV   Very Severe COPD   FEV1 /FVC < 0.70 
FEV1< 30 % predicted 
Adapted from Global strategy for the diagnosis, management, and prevention of Chronic Obstructive 
Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2007. 
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The different stages of COPD disease severity, based on GOLD guidelines are1 
Stage I, Mild COPD: Characterized by mild airflow limitation, with or without chronic 
cough and sputum production.  At this stage, the individual is usually unaware that his or 
her lung function is abnormal. 
Stage II, Moderate COPD: Characterized by worsening airflow limitation, with 
shortness of breath typically developing on exertion, cough and sputum production may 
be present sometimes.  At this stage, patients typically seek medical attention because of 
chronic respiratory symptoms or an exacerbation of their disease. 
Stage III, Severe COPD: Characterized by further worsening of airflow limitation, 
greater shortness of breath, reduced exercise capacity, fatigue, and repeated exacerbations 
that almost always have an impact on patient’s quality of life (QoL). 
Stage IV, Very Severe COPD: Characterized by severe airflow limitation and presence 
of respiratory failure.  This may also lead to effects on the heart such as cor pulmonale 
(right heart failure).  At this stage, QoL is very appreciably impaired and exacerbations 
may be life threatening.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
9
Health-care interventions to reduce risk factors 
Reduction of exposure to tobacco smoke, occupational dusts and chemicals, and 
indoor and outdoor air pollutants; is essential for preventing the onset and progression of 
COPD.  This can be achieved with the help of public health initiatives including smoking 
cessation, and protective steps taken by individual patients.  It is suggested that 
interventions that improve COPD outcomes by decreasing symptoms and preventing 
acute exacerbations could substantially decrease the costs associated with COPD.18    
The GOLD guidelines recognize smoking cessation as the single most effective 
and cost-effective intervention in most people, to reduce the risk of developing COPD 
and stop its progression.  A review of data from several countries estimated the median 
societal cost of various smoking cessation interventions at $990 to $13,000 per life year 
gained.19   
In the US, it is estimated that up to 19% of COPD in smokers and up to 31% of 
COPD in nonsmokers may be attributable to occupational dust and fume exposure.1  
Many occupationally induced respiratory disorders can be reduced or controlled through 
strategies such as controlled airborne exposure at workplace and other strategies aimed at 
reducing the burden of inhaled particles and gases.1 
 
Management of stable COPD  
GOLD has outlined guidelines for management of COPD.  Pharmacotherapy is 
used in COPD for preventing and controlling symptoms, reducing the frequency and 
severity of exacerbations, improving health status, and improving exercise tolerance.1  A 
step-wise treatment strategy is used in management of COPD, according to which the 
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medications are presented in an order, based on the level of disease severity and clinical 
symptoms.1  (Figure 1)  The selection within each class of medication depends upon 
individualized assessment of disease severity and the patient’s response. 
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Figure 1: Therapy at different stages of COPD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Global strategy for the diagnosis, management, and prevention of Chronic Obstructive 
Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2007. 
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Active reduction of risk factor(s); influenza vaccination 
Add short-acting bronchodilator (when needed) 
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Pharmacologic treatments 
          The classes of medications commonly used in treating COPD are  
• Bronchodilators (short and long acting) 
β2 agonists: Albuterol (short acting), Salmeterol (long acting) 
Anticholinergics: Ipratropium (short acting), Tiotropium (long acting) 
Methylxanthines: Theophyline, Aminophylline 
• Inhaled glucocorticosteroids: Beclomethasone, Fluticasone. 
 
Bronchodilators  
 Bronchodilators are central to the symptomatic management of COPD.  They are 
prescribed on an as-needed basis or on a regular basis to prevent or reduce symptoms and 
exacerbations.  The choice between β2 agonists, anticholinergics, and methylxanthines, or 
combination therapy depends on the availability and the individual’s response in terms of 
symptom relief and side effects.  Combining bronchodilators may improve efficacy and 
decrease the risk of side effects compared to increasing the dose of a single 
bronchodilator.  Regular treatment with long-acting bronchodilators is more effective and 
convenient than treatment with short-acting bronchodilators.1 
 
Glucocorticoids  
Long term treatment with systemic glucocorticoids may cause side-effects such as 
steroid myopathy in patients with advanced COPD. Thus chronic treatment with systemic 
glucocorticoids should be avoided because of the unfavorable benefit-to-risk ratio.  
However, the addition of regular treatment with inhaled glucocorticoids to bronchodilator 
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treatment is appropriate for symptomatic COPD patients with severe COPD, very severe 
COPD, and those with repeated exacerbations. 
Other pharmacologic treatments  
Other pharmacologic treatments used in the management of COPD include use of 
vaccines, immunoregulators, antitussives, vasodilators and several other medications 
which help in relieving symptoms and reducing the severity of exacerbations.  Influenza 
vaccines can reduce serious illness and death in COPD patients by about 50%.1  Influenza 
vaccination has also been shown to reduce the risk of hospital admission and death in 
elderly subjects with chronic lung disease.20   
 
Non pharmacologic treatments  
Non pharmacologic treatments include pulmonary rehabilitation, oxygen therapy, 
ventilatory support, and surgical interventions.1 
 
Pulmonary rehabilitation  
A pulmonary rehabilitation program includes exercise training, nutrition 
counseling and education.  Pulmonary rehabilitation covers a range of non-pulmonary 
problems (exercise de-conditioning, depression, muscle wasting, and weight loss) that 
may not be adequately addressed by medical therapy for COPD.  Pulmonary 
rehabilitation has shown to reduce symptoms, anxiety and depression associated with 
COPD.  It has  also reduced the number of hospitalizations, hospital length of stay, and 
improved quality of life, and increased physical and emotional participation in everyday 
activities.1 
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Oxygen therapy  
It is one of the principal nonpharmacologic treatments for patients with very 
severe COPD.  It can be administered in three ways: long-tem continuous therapy, during 
exercise, and to relieve acute dyspnea.  In patients with chronic respiratory failure, the 
long-term administration of oxygen (> 15 hours per day) has shown to increase 
survival.21  
 
Ventilatory support  
Noninvasive ventilation is now widely used to treat acute exacerbations of COPD. 
 
Surgical treatments  
Surgical treatments used in patients with COPD include bullectomy, lung volume 
reduction surgery (LVRS), and lung transplantation. 
 
Bullectomy  
Bullectomy is used for bolus emphysema, and can be performed 
thoracoscopically.  It is effective in reducing dyspnea and improving lung function in 
carefully selected patients. 
 
Lung volume reduction surgery (LVRS)  
In LVRS, parts of the lung are resected to reduce hyperinflation, making 
respiratory muscles more effective pressure generators by improving their mechanical 
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efficiency.  LVRS also increases the elastic recoil pressure of the lung and improves 
expiratory flow rates.  It is an expensive palliative surgical procedure and can be 
recommended only in carefully selected patients. 
 
Lung transplantation  
Lung transplantation has been shown to improve quality of life and functional 
capacity in appropriately selected patients. 
 
 
Management of Exacerbations  
The impact of exacerbations is significant, and inhaled bronchodilators and oral 
glucocorticosteroids are effective treatments for exacerbations of COPD.  During 
exacerbations, noninvasive mechanical ventilation has shown to improve respiratory 
acidosis, decrease respiratory rate, severity of breathlessness, and decrease length of 
hospital stay.1 
 
PROBLEM STATEMENT 
 
In 2000, COPD was responsible for eight million physician office and hospital 
outpatient visits, 1.5 million emergency department visits, and 726,000 hospitalizations, 
and 119,000 deaths in the US.7, 9  It is a leading cause of hospitalization in the older 
population.18  Hospital admissions for COPD are mainly due to disease exacerbations and 
respiratory failure.22  The rate of hospital readmissions is also particularly high for 
exacerbations of COPD, with over half of the patients who are hospitalized for 
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exacerbations of COPD, being readmitted at least once in the following 6 months and a 
majority of readmissions occurring within the first 3 months after hospital discharge.23 
The frequency of readmission varies from 11.6% (48 hours after discharge from the 
emergency room) to 63% (one year after admission to a general hospital).24  Because 
hospitalization in patients with COPD usually occur in the later stages of the disease, it is 
associated with a greater risk of mortality in the subsequent years.25  Mortality was found 
to be 60% one year after hospitalization in patients 65 years and older, who were 
hospitalized for exacerbation of COPD.25   
As discussed earlier, hospitalizations account for a major portion of the total cost 
of care in patients with COPD.1, 4  Some studies show that the cost of hospital stay 
represents 40-57% of the total direct costs generated by patients with COPD, reaching up 
to 63% in severe patients.26, 27  During an exacerbation, health-care utilization is usually 
significantly increased, and thus, exacerbations are the key drivers of the costs of 
COPD.16 
The disparities in hospital resource utilization and factors associated with 
hospitalization in COPD are poorly understood.24, 29-35   The influence of gender on the 
susceptibility to and mortality from COPD is controversial.  Some studies show an 
increased risk of death in men with COPD, while other studies suggest that men are less 
likely to die from COPD than women.29, 31, 32  There is a dearth of studies which have 
done stratified analyses in the US population, to determine the effect of COPD according 
to race, type of hospital, insurance, and socioeconomic status on the resulting differences 
in health-care access, and on the risk of hospitalization and death .   
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There is also a lack of information about differences between hospital types with 
respect to length of stay (LOS) and mortality in a national sample in the US.  Hence, in 
this study, we will look at the characteristics of the patient population with COPD 
utilizing hospital resources and evaluate the factors responsible for hospital resource 
utilization, in-hospital mortality, and total hospitalization costs due to COPD.  A study of 
the rates of hospitalizations and duration of such hospital stays, due to COPD, can help us 
understand the characteristics of the patient population and their level of resource 
utilization.   
Hospitalization for COPD could be avoided with appropriate management, use of 
preventative care and early disease management.24  The study findings can help us 
identify a subset of patients with COPD that could benefit best from an active 
interventional program or a therapeutic strategy, which may help lowering hospital 
readmission rates and costs, thereby reducing the economic burden of the disease.   
 
CONCEPTUAL FRAMEWORK 
 
The objective of this study is to develop a national assessment of hospital 
resource usage in patients with COPD, using retrospective data derived from Nationwide 
Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP).  The 
study will determine COPD- related hospitalizations using inpatient discharge-level data 
for 100% of the discharges from a sample of hospitals in participating states, in terms of 
patient and hospital characteristics.  Temporal patterns (for years 2002-2005) of hospital 
LOS, mortality during hospitalization, and total hospital costs due to COPD- related 
hospitalizations will be identified. 
  
 
 
18
 
The HCUP database was established by the Agency for Healthcare Research and 
Quality (AHRQ) to provide multi-state, administrative, population-based data.  It 
contains set of information found in a typical discharge abstract including all listed 
diagnosis and procedures, discharge status, patient demographics, and charges for all 
patients- insured and uninsured in a uniform format. 
HCUP provides five types of databases: 
The State Inpatient Database (SID): It contains the universe of inpatient discharge 
abstracts from community hospitals of the participating states. 
The State Ambulatory Surgery Database (SASD): It contains data from ambulatory 
care encounters in hospital-affiliated and sometimes freestanding ambulatory sites. 
The State Emergency Department Database (SEDD): It contains data from hospital 
affiliated emergency department abstracts for visits that do not result in a hospitalization. 
The Kid’s Inpatient Database (KID): It contains a nationwide sample of inpatient 
discharges of patients 18 years and younger. 
The Nationwide Inpatient Sample (NIS): It is the largest all-payer inpatient care 
database containing data from 5 to 8 million hospital stays from about 1000 hospitals 
sampled to approximate a 20% stratified sample of US community hospitals. 
We would be using the NIS database for our study. 
The NIS is available from 1988 to 2005.  It is the only national hospital database 
with charge information on all patients, regardless of payer, including persons covered by 
Medicare, Medicaid, private insurance and the insured.  Researchers and policymakers 
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use the NIS to identify, track, and analyze national trends in healthcare utilization, access, 
charges, quality and outcomes. 
The NIS contains patient-level clinical and resource use information included in a 
typical discharge abstract.  The NIS includes specialty hospitals such as obstetrics-
gynecology, ear-nose-throat, short term rehabilitation, orthopedic, pediatric, public 
hospitals and academic medical centers.  Excluded are long term hospitals, psychiatric 
hospitals, alcoholism/chemical dependency treatment and short term rehabilitation 
(beginning with 1998 data).  The community hospitals are divided into strata using five 
hospital characteristics: ownership/control, bed size, teaching status, urban/rural location 
and US region. 
 
OVERALL HYPOTHESIS 
 
 The overall hypothesis of this study is that disparities exist in hospital resource 
utilization and mortality among patients with COPD. 
 
STUDY OBJECTIVES 
 
The specific objectives of this study would be: 
1. To calculate and compare weighed averages for hospital length of stay (LOS), 
total hospital costs, and in-hospital deaths; related to COPD as a primary and 
secondary diagnosis using the 2005 NIS database. 
2. To study the COPD-related hospitalizations in terms of patient and hospital 
characteristics using the 2005 NIS database. 
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3. To study the differences in the COPD-related hospital length of stay (LOS) by 
patient and hospital characteristics using the 2005 NIS database. 
4. To study the differences in the COPD-related hospital costs by patient and 
hospital characteristics using the 2005 NIS database. 
5. To study the differences in the COPD-related in-hospital mortality by patient 
and hospital characteristics using the 2005 NIS database. 
6. To identify predictors of COPD-related length of stay (LOS), in terms of 
patient and hospital characteristics using the 2005 NIS database. 
7. To identify predictors of COPD-related total hospital costs, in terms of patient 
and hospital characteristics using the 2005 NIS database. 
8. To identify predictors of in-hospital mortality in patients with COPD, in terms 
of patient and hospital characteristics using the 2005 NIS database. 
9. To study the temporal pattern of COPD-related hospital length of stay (LOS), 
total hospital costs, and in-hospital deaths; between years 2002-2005, using 
the NIS database. 
 
SIGNIFICANCE OF THE STUDY 
 
This study can help us identify the characteristics of patients with COPD , who 
would benefit most from the interventional programs or preventive disease management 
strategies.  Also the study results can help us understand if there are disparities in access 
to care in patients with COPD.  This can help health care professionals in designing 
health care policies and interventions targeting these high risk populations. This may 
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eventually help in delaying the progression of disease, preventing exacerbations and the 
subsequent hospitalizations, reducing mortality in such population, and thus, alleviating 
the economic burden associated with COPD.  
Assessing patient- and hospital-related characteristics in COPD will help 
understand the factors that influence the rate of hospital admissions, and the total cost of 
hospitalization.  This will further help assist health care professionals in making 
important decisions regarding the management COPD, and eliminating COPD disparities. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
This chapter reviews the literature found on COPD-related hospitalizations and 
important outcomes such as hospital LOS, total hospital charges, and in-hospital 
mortality due to COPD-related hospitalizations.  Information on trends in COPD-related 
hospitalizations and predictors of such outcomes, have also been included in this chapter.   
In addition, studies which have looked at cost of care in patients with COPD and 
exacerbations of COPD were also reviewed here. 
 
The studies found in the literature review were categorized as: 
1. Trends in COPD-related hospitalizations and mortality. 
2. Factors responsible for or predictors of COPD-related hospitalizations and 
mortality. 
3. Costs of managing exacerbations and COPD-related hospitalizations 
 
Trends in COPD‐related hospitalizations and mortality 
Mannino and colleagues (2002) used data from national health surveys conducted 
by National Center for Health Statistics (NCHS) to report trends in different measures of 
COPD during 1971-2000.  The results in the COPD surveillance summary report showed 
that during 2000, COPD was responsible for 726,000 hospitalizations and 119,000 
deaths.  The most substantial change was an increase in the mortality rate due to COPD 
in women; from 20.1/100,000 in 1980 to 56.7/100,000 in 2000.  There was a more 
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modest increase in the mortality rate for men; from 73.0/100,000 in 1980 to 82.6/100,000 
in 2000.  Also in 2000, the number of women dying from COPD exceeded the number of 
men for the first time.  During the study period, the overall death rate for COPD 
increased 67%.  The results also showed that the hospitalization rates for COPD among 
Caucasians were greater than those among African Americans during 1980-1987, after 
which rates have been similar.  Hospitalization rates for men were greater than females 
through 1980s; however, since 1995, these rates have been similar.  Since 1990, 
hospitalization for COPD have increased among all age groups, with the largest increase 
observed for those aged 65-74 years (62%) and those ≥75 years (52%).28 
Saynajakangas and colleagues (2004) conducted a retrospective study to assess 
the trends in the duration of inpatient episodes following emergency admissions for 
COPD.  The hospital discharge register maintained by the Finnish National Research and 
Development Center for Welfare was investigated.  Records of emergency admissions of 
patients aged over 44 years (n = 72,672) that ended during 1993-2001 and had COPD as 
the principal diagnosis were included in the analysis.  The results showed that the mean 
age on admission was 72.1 years (SD 8.7) in 2001.  The average hospital LOS was 7.8 
days (SD 7.6), being 8.5 days (SD 8.2) in 1993 and 6.8 days (SD 6.6) in 2001, indicating 
a decrease in LOS for COPD exacerbations.  Elderly women (aged 64 years and older) 
had the longest inpatient episodes (LOS = 8.8 days).  A total of 12.1% of the patients had 
10 or more inpatient episodes.  It was also reported that a 1-week stay in hospital resulted 
in the longest interval to readmission.29 
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Predictors of COPD‐related hospitalizations 
McGhan and colleagues (2007) used the Veteran’s Affair health-care system to 
determine the predictors of rehospitalization and mortality rates in patients with COPD.  
They used data for inpatient stays; and a sample of 51,353 patients was included in the 
study.    Only those, who were hospitalized for COPD and discharged between years 
1999-2003, were included in the study.  The two primary outcomes that were studied 
were time to death and time to death in the time frame of six years.  The study results 
showed that the majority of patients (63%) had a history of prior hospitalization, and a 
history of non-COPD hospitalization was more common than a history of hospitalization 
for COPD.  Many patients had multiple subsequent stays for COPD, with a mean LOS of 
6.5 days.  The risk of rehospitalization for COPD was 25% at 1 year, and 44% at 5 years.  
The risk of mortality was found to be considerable in the cohort, with the risk of death 
21% at 1 year, and 55% at 5 years.  Increasing age, being male, number of prior 
hospitalizations, and certain comorbidities including asthma and pulmonary hypertension 
were found to be risk factors for death and rehospitalization in patients discharged after a 
severe exacerbation.  Noncaucasian race and other comorbidities were associated with a 
decreased risk.30  
 
Chen and colleagues (2005) used the Person Orientated Information Database, 
which contains the hospital discharge data from all Canadian provinces in a retrospective 
cohort study.  Participants included 257,604 COPD patients in the 3-year study period 
(1994-1997).  The results showed 142,770 hospitalizations due to COPD as primary 
diagnosis, and 463,089 hospitalizations for COPD listed as one of the five underlying 
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diagnosis.  Overall, men were more likely to have hospitalizations for COPD and had a 
higher proportion of death at hospital than women.  The relative risk for women versus 
men gradually increased with decreasing age, and was significantly greater in the 55-59 
year group for hospitalizations due to COPD as a primary diagnosis.  The researchers 
also believed that there was a growing body of evidence for a possibility of increased 
susceptibility to COPD in response to tobacco smoke in women.31 
 
Prescott and colleagues (1997) examined data from the Copenhagen City Heart 
Study (CCHS).  The subjects were administered a questionnaire assessing their level of 
education, household income, tobacco consumption, pulmonary symptoms, and 
measurement of lung function by spirometry.  The results indicated that socio-economic 
status, measured by income and educational level, is significantly associated with 
admission to hospital for COPD.  The age adjusted relative risks of admission to hospital 
for COPD, in the lowest socioeconomic group was approximately three-fold higher than 
in the highest group, and was similar in females and males.  The study results indicated 
that socioeconomic factors affected the adult risk of developing COPD, independently of 
smoking status in both females and males.32 
 
Holguin and colleagues (2005) used the National Hospital Discharge Survey data 
(1979 to 2001); to study the prevalence of co-morbidities and in-hospital mortality of 
patients with COPD.  During the study period, there were an estimated 47,404,700 
hospital discharges; of which 20.8% had COPD as the primary diagnosis, and 79.2 % had 
COPD as a secondary diagnosis.  It was concluded that any mention of COPD in the 
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discharge diagnosis is associated with higher hospitalization prevalence and in-hospital 
mortalities.17 
 
Ansari and colleagues (2007) computed age- and gender-standardized hospital 
admission rates of COPD for years 2003-2004 in Australia, using the Victorian Admitted 
Episodes Dataset.  Hospital admission rates for COPD were found to be higher in rural 
areas of Victoria than in metropolitan areas.  Multiple regression analysis showed 
significant association between COPD admission rates and socio-economic status, 
smoking rates, and remoteness of area.33 
 
An audit study of acute hospital care of COPD was conducted in the UK by 
Hosker and colleagues (2007).  The audit was run jointly by the Clinical Effectiveness 
and Evaluation unit of the Royal College of Physicians and the British Thoracic Society.  
The audit showed that, despite the publication of standards and guidelines for the 
management of COPD, there remained marked between-hospital variability in all aspects 
of acute inpatient COPD care.  The type and severity of patients admitted to large, 
medium, and small units were similar, but the organization and facilities available for 
those patients were not.  In addition, the process of care and outcomes appeared worse in 
smaller hospitals.34 
 
 The results of another pilot study conducted by Roberts et al (2003) in England 
and Wales also showed that better survival was seen in teaching and larger hospitals; 
suggesting that significant differences in mortality in acute COPD may exist between 
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hospital types.  Thirty hospitals were randomly selected by geographical region and 
hospital types (teaching, large and small district general hospital [DGH]).  Data on 
process and outcomes of care including death and LOS was collected, both 
retrospectively and prospectively.  Small DGHs were seen to have a higher mortality 
(17.5%) than teaching hospitals (11.9%) and large DGHs (11.2%).35 
 
Cost of exacerbations and hospitalizations 
Some studies show that the cost of hospital stay represents 40-57% of the total 
direct costs generated by patients with COPD, reaching as high as 63% in severe patients. 
28, 29 Miravitlles and colleagues (2003) conducted a prospective one-year follow-up study 
on a large cohort of patients (n = 1,510) with chronic bronchitis and COPD, recruited 
from general practices located throughout Spain.  All direct medical costs incurred by the 
cohort and related to their respiratory disease were reviewed.  They reported that the 
mean direct annual cost of chronic bronchitis and COPD was $1,876, and hospitalization 
costs represented 43.8% of these costs.  The cost of severe COPD ($2,911) was almost 
double that of mild COPD ($1,484).  Hospitalization accounted for 41.2% and 46.8% of 
the total costs for mild COPD and severe COPD respectively.  They also reported that the 
cost of chronic bronchitis and COPD were almost twofold of those reported for asthma.27 
 
Hilleman and colleagues (2000) used a retrospective study design in a university 
teaching hospital setting.  A cost of illness analysis was conducted using health-care 
resource utilization data and costs identified through chart review.  Severity of COPD 
was stratified using the American Thoracic Society stages I, II, and III.  The study 
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demonstrated a strong correlation between disease severity and total treatment cost in 
COPD, with stage I having the lowest cost.  The study also demonstrated that the type of 
bronchodilator therapy also impacts total cost in COPD.  Hospitalization was the most 
important cost variable for all three stages of COPD severity.  The study results 
supported the notion that adherence to published treatment guidelines in COPD resulted 
in lower health-care costs.14  The annual median treatment costs per patient per year 
across different stages of COPD were as follows: (See Table 2) 
 
Wilson and colleagues (2000) used a prevalence approach and a societal perspective to 
estimate the annual direct medical costs of COPD (specifically chronic bronchitis and 
emphysema) in 1996, in the US.  The authors used multiple national, state, and local data 
sources to estimate the health-care utilization and costs.  The annual direct medical costs 
of COPD were $14.5 billion in 1996 dollars.  Total inpatient costs were $8.3 billion (57% 
of total costs) while outpatient and emergency care were $5.8 billion (40% of total costs), 
and home and institutional care was only $0.34 billion.  The largest costs were for 
inpatient hospital stays ($7.8 billion, 54% of total costs).36  Hospital inpatient utilization 
and costs by disease (chronic bronchitis and emphysema) in 1996, are indicated in Table 
3.  
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Table 2: Annual median treatment costs incurred over the entire duration of follow-
up and stratified by severity of COPD. 
 
   Severity of COPD        Hospitalization cost*           Total cost 
  
    
   Stage I    $680   (40%)    $1,681 
   Stage II    $2,658 (53%)    $5,037 
   Stage III    $6,770 (63%)    $10,812 
Hilleman and colleagues (2000) 
*Costs presented as per patient per year (percentage of total costs) 
 
 
Table 3: Hospital utilization and related costs, by disease. 
 
Disease             No. of discharge  Length of stay        Hospitalization         Total costs  
                (in thousands)    (in days)              rate (%)      (in billions) 
 
COPD         1,465       7.06    8.93%           8.3 
CB         1,168       6.97    8.15%           6.3 
Emphysema          296       7.92    14.3%           2.0 
Wilson and colleagues (2000)  
COPD= Chronic Obstructive Pulmonary Disease. 
CB= Chronic Bronchitis 
 
 
 
 
 
  
 
 
30
In another study of COPD-related costs, Sullivan and colleagues (2000) studied 
the National Medical Expenditure Survey and indicated that inpatient hospitalization and 
emergency department care formed the largest proportion (72.8%) of total expenditure.  
Only 10% of persons with COPD accounted for more than 70% of all medical care costs.  
The study also reported that international studies of trends in COPD-related 
hospitalization indicated that although the average LOS had decreased since 1972, 
admissions per 1,000 persons per year for COPD had increased in all age groups  45 
years and older.37 
 
Health-care utilization is usually significantly increased during an exacerbation 
and thus, exacerbations are considered the key drivers of costs in COPD.38 
Miravitlles and colleagues (2002) conducted pharmacoeconomic evaluation of 
acute exacerbations of chronic bronchitis and COPD using a prospective study design in 
an ambulatory setting, in Spain.  The study results showed that the total direct mean cost 
of all exacerbations was $159, and patients who were hospitalized generated 58% of the 
total cost. Cost per treatment failure, defined as the need of a new medical contact for 
persistence or aggravation of symptoms during the 30 days after initiating treatment, was 
$477.50.  Thus, 63% of the total costs associated with the management of exacerbation 
were costs derived from treatment failure.  Sensitivity analysis showed that, when 
treatment failure is reduced to zero, the average cost of treatment of an exacerbation 
would decrease from $159 to only $58.7.4 
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Although, there is a body of literature which reflect on the differences in 
outcomes for respiratory diseases, such as asthma and lung cancer; there is very little 
information about disparities in COPD care.39   Several patient characteristics like age, 
gender, race, comorbidities, disease severity, and prior hospitalizations have been 
identified as predictors of outcomes like LOS, in-hospital mortality, and total costs in 
hospitalizations due to COPD.  Some correlation between the hospital characteristics 
such as hospital type and location, and the outcomes, was also seen.  However, no study 
has been conducted that gives a detailed overview of disparities among patients with 
COPD, based on the patient and hospital characteristics; at a national level. Also, it has 
not been studied whether patient’s type of insurance or their socioeconomic status (SES) 
can be one of the predictors of hospital LOS, mortality, and the total costs of 
hospitalization in patients with COPD.  The present study aims to retrospectively 
determine hospital LOS, mortality, total hospital charges, and trends in these outcomes; 
in patients hospitalized with COPD.   A descriptive analysis of different patient- and 
hospital-related characteristics that affect these outcomes using the Nationwide Inpatient 
Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP) data will be 
conducted. 
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CHAPTER THREE 
METHODOLOGY 
Data Source 
Healthcare Cost and Utilization Project (HCUP) 
The HCUP is a family of health care databases and related software tools 
developed through a Federal-State-Industry partnership to build a multi-state health data 
system for health care research and decision-making.  The HCUP sponsored by the 
Agency for Healthcare Research and Quality (AHRQ), contains a core set of clinical and 
nonclinical information found in a typical discharge abstract.  The information is 
translated into a uniform format with privacy protections in place.  HCUP includes the 
largest collection of longitudinal hospital care data in the US, with all-payer, encounter-
level information beginning in 1988.  The HCUP databases enable research in different 
areas such as health policy issues, including cost and quality of health services, medical 
practice patterns, access to health care programs, and outcomes of treatments at the 
national, state, and local market levels.  
The Nationwide Inpatient Sample (NIS), one of the datasets of HCUP, was used 
in this study.  The NIS is the largest all-payer inpatient dataset that includes information 
on all discharge data from a national sample of more than 1,000 hospitals.  All discharges 
from sampled hospitals are included in the NIS database.  The NIS is available from 1988 
to 2005.  It is the only national hospital database with charge information on all patients, 
regardless of payer, including persons covered by Medicare, Medicaid, private insurance 
and the uninsured.  Inpatient stay records in the NIS include patient-level clinical and 
resource use information included in a typical discharge abstract.  Hospital and discharge 
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weights are provided for producing national estimates.  The NIS contains discharge-level 
records, not patient-level records.  Thus, individual patients who are hospitalized multiple 
times in one year may be present in the NIS multiple times.  There is no uniform patient 
identifier available that allows a patient-level analysis with the NIS. 
  The NIS is designed to approximate a 20% stratified sample of US community 
hospitals.  The American Hospital Association (AHA) defines community hospital as “all 
non-federal, short term, general and other specialty hospitals, excluding hospital units of 
institutions.”  The NIS includes specialty hospitals such as obstetrics-gynecology, ear-
nose-throat, short term rehabilitation, orthopedic, pediatric, public hospitals and academic 
medical centers.  Excluded are long term hospitals, psychiatric hospitals, 
alcoholism/chemical dependency treatment and short term rehabilitation (beginning with 
1998 data).  The community hospitals are divided into strata using five hospital 
characteristics: ownership/control, bed size, teaching status, urban/rural location and US 
region.  Researchers and policymakers use the NIS to identify, track, and analyze national 
trends in healthcare utilization, access, charges, quality and outcomes. 
From the NIS dataset for each year, the inpatient core data file was utilized.  This 
inpatient discharge-level file contains data for 100% of the discharges from a sample of 
hospitals in participating states, and the unit of observation is an inpatient stay record.  To 
address some of the objectives, the hospital weights file was also used from the NIS 
dataset.  It contains weights and variance estimation data elements, as well as linkage 
data elements, and the unit of observation is the hospital.  Data elements from both these 
files were used to create a final dataset, to be used for analysis in this study.  The 
summary for the NIS datasets used in the study are given in Table 4. 
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Table 4: Summary of NIS datasets 
 
Year      Data from             Number                  Number of                         Number of  
                                           of hospitals                discharges,                        discharges,  
                      unweighed                       weighed for 
              national estimates 
 
2002            35 states                  995                  7,853,982                      37,804,021 
2003            37 states                  994                   7,977,728                      38,220,659 
2004            37 states                1,004        8,004,571                       38,661,786 
2005            37 states                1,054                   7,995,048                       39,163,834 
Adapted from Introduction to the HCUP NIS, available on the HCUP-US website http://www.hcup-
us.ahrq.gov 
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The NIS contains several clinical and non-clinical data elements for each hospital 
stay.  Data elements in the NIS Inpatient Core file include admission and discharge 
information, patient demographics (e.g., gender, age, race, median household income for 
ZIP code, location), diagnoses information, procedure information, expected payment 
source, total hospital charges, length of stay (LOS), and hospital information (e.g. the 
HCUP hospital identification number which provides the linkage between the NIS 
Inpatient Core files and the Hospital Weights file).  The NIS Hospital Weights file 
contains data elements which include discharge weights (which can be used to create 
national estimates), the HCUP hospital identifiers, and hospital characteristics (bed size, 
location, teaching status, region. 
 
Patient population 
The NIS from HCUP for the years 2002, 2003, 2004 and 2005 were used.  The 
NIS data obtained from HCUP was extracted and the Inpatient Core discharge-level files 
containing 100% of the discharges from a sample of hospitals in participating states were 
used.  The Hospital Weights file, which helps to account for the complex sampling frame 
of the NIS dataset, was used. The Cost-charge ratio file, which helps to translate the 
hospital charges in the dataset into actual costs, was also used.  Individuals from this 
sample having the primary or secondary diagnosis as COPD (as defined by the 
International Classification of Diseases, 9th Revision ICD-9 code) was then selected.  
Thus, all hospitalizations with primary or secondary diagnosis (only the first and the 
second diagnostic listing) with ICD-9 codes 490-492 and 496 were extracted and merged, 
to form our final dataset that was used for the several objectives of our study.                                                   
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Data extraction 
The NIS data obtained from the HCUP was extracted by decompressing the data 
and unzipping the required necessary files such as NIS Inpatient Core and Hospital 
Weights files. These files which were in ASCII format were converted to Statistical 
Package for Social Sciences (SPSS)(version 16.0) for analytical purposes.  The 
conversion of ASCII to SPSS format was done with the help of SPSS Load Programs 
obtained in the NIS documentation files available on the HCUP-US website. 40   From 
this main data, only individuals having COPD were selected.   Individuals from this 
sample having a primary or secondary diagnosis of COPD (as defined by the ICD-9 code) 
were then selected.  This dataset was used as the final dataset for the several objectives of 
this study.  The same extraction procedure was applied to all datasets for each of the four 
years. 
 
Patient‐Level Variables 
Patient-level variables that were included in the analysis were age, race, gender, 
payer information, location of patient, and median household income.  These variables 
were described by the NIS as: 
Age at admission 
Age at admission, was coded 0-124 years in HCUP.  Age at admission was 
calculated from the date of birth and the admission date.  It was considered invalid if it 
was out of range (0-124 years) or it could not be calculated.  For the purpose of our 
analysis, age was categorized in different age groups: 0-20 years, 21-40 years, 41-64 
years, 65-80 years, and 80 years and above.  These levels of age were categorized to 
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reflect access to Medicare (starting after age 65). 
 
Race  
Both race and ethnicity are included in one data element as ‘Race’ in HCUP.  In 
HCUP, the variable race is categorized into Caucasian, African American, Hispanic, 
Asian or Pacific Islander, Native American, and others.  For regression analyses in our 
study, race was categorized into the following four groups: Caucasian, African American, 
Hispanic and Others.  
 
Gender  
The gender variable was used as an indicator of sex of the hospitalized patient.  
 
Payer information  
The payer variable indicates the expected primary payer.  In HCUP, to ensure the 
uniformity of coding across data sources, this variable combines detailed categories in the 
more general groups like Medicare, Medicaid, Private insurance, self pay, no charge and 
other.  For example, Medicare includes both fee-for-service and managed care Medicare 
patients.  Medicaid too includes both fee-for-service and managed care Medicaid 
patients.  Private insurance includes Blue Cross, Commercial carriers, and private health 
maintenance organizations (HMOs) and preferred provider organization (PPOs).  Other 
includes Worker’s compensation, The Civilian Health and Medical Program of the 
Uniformed Services (CHAMPUS), The Civilian Health and Medical Program of the 
Department of Veterans Affairs (CHAMPVA), and other government programs.  
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Patient Location  
The patient location variable is a four category urban-rural designation for the 
patient’s county of residence.  The 12 categories of the Urban Influence Codes (UIC) are 
combined into four broader categories: large metropolitan areas with at least 1 million 
residents, small metropolitan areas with less than 1 million residents, micropolitan areas 
(non-metro areas either adjacent to large metro or small metro or not adjacent to any 
metro area), and non-urban areas (non-core areas either adjacent or not adjacent to a 
metro or a micro). 
 
Median household income  
This variable is the median household income for patient’s ZIP code (based on 
current year) and provides a quartile classification of the estimated median household 
income of residents in the patient’s ZIP code.  Quartiles are identified by the values of 1 
to 4 indicating poorest to the wealthiest population.  Since these estimates are updated 
annually, the value ranges vary by year.  Dollar ranges represented by each category are 
shown in Table 5. 
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Table 5: Levels of median household income quartiles for patient’s ZIP codes. NIS 
2002‐2005  
 
Year    Quartile 1($)           Quartile 2 ($)         Quartile 3 ($)               Quartile 4 ($) 
 
 
  2002        1-35,999              36,000-45,999           46,000-61,999              ≥ 62,000 
  2003        1-35,999              36,000-45,999           46,000-59,999              ≥ 60,000 
  2004        1-35,999              36,000-45,999           46,000-58,999              ≥ 59,000 
  2005        1-36,999              37,000-45,999           46,000-60,999              ≥ 61,000 
Adapted from Introduction to the HCUP NIS, available on the HCUP-US website http://www.hcup-
us.ahrq.gov 
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Hospital‐Level Variables 
 Hospital-level variables such as geographic region, location, teaching status, and 
hospital bed size were utilized for the purpose of the study.  These variables were 
obtained from the NIS Hospital Weights file, and the HCUP hospital identification 
number was used to provide the linkage between the NIS Inpatient Core files and the 
Hospital Weights file.  
In NIS, the NIS Stratum is a four-digit stratum identifier used to post-stratify 
hospitals for the calculation of universe and frame weights.  The NIS Stratum includes the 
hospital census region, ownership/control, location/teaching status, and bed-size; all 
combined into one variable.  Information on the hospital variables was obtained from the 
American Hospital Association (AHA) Annual Survey of Hospitals.  For the purpose of 
analysis in this study, the hospital level variables were looked at separately: 
 
Geographic region 
The hospital's geographic region was classified into four categories: Northeast, 
Midwest, South, and West.  This information was obtained from the AHA Annual Survey 
of Hospitals, and the geographic region was defined by the U.S. Census Bureau.  This is 
an important stratifier because practice patterns have been shown to vary substantially by 
region.  For example, lengths of stay tend to be longer in East Coast hospitals than in 
West Coast hospitals.40 
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Table 6:  All states by Region, NIS 2005 
 
 Region    States 
Northeast   Connecticut, Maine, Massachusetts, New Hampshire, New Jersey,  
New York,  Pennsylvania, Rhode Island, Vermont. 
 
Midwest  Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, 
Nebraska, North Dakota, Ohio, South Dakota, Wisconsin. 
 
South              Alabama, Arkansas, Delaware, District of Columbia, Florida,       
                                    Georgia, Kentucky, Louisiana, Maryland, Mississippi, North  
                                    Carolina, Oklahoma, South Carolina, Tennessee, Texas, 
                                    West-Virginia. 
 
West  Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, 
Nevada, New Mexico, Oregon, Utah, Washington, Wyoming. 
 
Adapted from Introduction to the HCUP NIS, available on the HCUP-US website http://www.hcup-
us.ahrq.gov 
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Location 
The hospital location is categorized as rural and urban.  Beginning with the 2004 data, 
the classification of urban or rural hospital location used the newer Core Based Statistical 
Area (CBSA) codes.  CBSA groups were based on 2000 Census data.  Hospitals residing in 
counties with a CBSA type of metropolitan were considered urban, while hospitals with a 
CBSA type of micropolitan or non-core were classified as rural.  Government payment 
policies often differ according to this designation.  Also, rural hospitals are generally smaller 
and offer fewer services than urban hospitals. 
 
Teaching status 
The hospital's teaching status was obtained from the AHA Annual Survey of 
Hospitals.  The missions of teaching hospitals differ from nonteaching hospitals.  In 
addition, financial considerations differ between these two hospital groups.  A hospital is 
considered to be a teaching hospital if it has an AMA-approved residency program, is a 
member of the Council of Teaching Hospitals (COTH) or has a ratio of full-time 
equivalent interns and residents to beds of .25 or higher. 
Rural hospitals were not split according to teaching status, because rural teaching 
hospitals were rare. 
 
Bed-size 
Bed-size categories are based on hospital beds, and bed-size assesses the number of 
short-term acute beds in a hospital.  Hospitals were classified on the basis of bed size as 
small, medium and large. Refer Table 7.  The hospital's bed-size category is nested within 
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location and teaching status, and is defined using region of the U.S, the urban-rural 
designation of the hospital, in addition to the teaching status. 
Table 7: Hospital bed size categories, by region. NIS 2005 
Location & Teaching status                         Hospital bed-size 
                                                                           
          Small      Medium           Large 
Northeast Region 
Rural           1-49         50-99            100+ 
Urban, Non-Teaching         1-124               125-199            200+  
Teaching          1-249               250-424             425+ 
 
Midwest Region 
Rural           1-29         30-49  50+  
Urban, Non-Teaching         1-74         75-174           175+ 
Teaching          1-249       250-374           375+ 
 
Southern Region 
Rural           1-39          40-74  75+  
Urban, Non-Teaching         1-99        100-199           200+ 
Teaching          1-249        250-449           450+ 
 
Western Region 
Rural           1-24          25-44  45+ 
Urban, Non-Teaching         1-99        100-174           175+ 
Teaching          1-199        200-324           325+ 
 
Adapted from Introduction to the HCUP NIS, available on the HCUP-US website http://www.hcup-
us.ahrq.gov 
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Other Variables related to Diagnoses, Procedures and Type of admission 
Other variables which can affect the patient’s hospital resource utilization, such as 
variables related to the diagnosis reported or procedures conducted were also considered 
in the analysis. 
 
Number of procedures 
The Number of Procedures (NPR) variable indicates the total number of ICD-9-
CM procedures coded on the discharge record.  A maximum of 15 procedures have been 
retained on a NIS inpatient record.  Some states provided fewer than 15 procedures on the 
discharge record; for example, if a state supplied 5 procedures, PR6 through PR15 are 
blank (" ") on all records from that state.  Whereas some states provide more than 15 
procedures, and these records may have information truncated.  If an inpatient record 
from these states had more than 15 non-missing procedures, procedures in positions 16 
and above was not included in the NIS file. 
 
Number of diagnoses on discharge record 
The Number of Diagnoses (NDX) variable indicates the total number of 
diagnoses coded on the discharge record.  Similar to NPR, a maximum of 15 diagnoses 
has been retained on a NIS inpatient record.  States that provide more than 15 diagnoses 
may have information truncated for this variable. 
 
Elective  
The ELECTIVE variable indicated, whether the admission to the hospital was 
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elective or non-elective.  This information was derived from another variable related to 
type of admission (ATYPE).  
Outcome Variables 
 The outcome variables that were included in this study were hospital length of 
stay (LOS), in-hospital deaths, total hospital costs, and principal procedures performed on 
a patient with COPD.  The total hospital charges were obtained from the Inpatient Core 
files and the Cost-to-Charge Ratio files were used to convert the charge data, and derive 
cost estimates of in-patient care.  Following is the information on these variables as 
provided by HCUP. 
 
Length of stay (LOS)   
LOS is calculated by subtracting admission date from the discharge date.  Same 
day stays are hence coded as 0.  The value of LOS ranges from 0-365 days.  
 
In-hospital death 
 This indicates whether the patient died during hospitalization.  It is coded from 
disposition of the patient, depending on whether the patient was discharged alive or if the 
patient died in the hospital. 
  
Total hospital charge/costs  
 The total hospital charge variable provides the value of a total hospital charge for 
a patient.  The total charge is rounded to the nearest possible figure, and the value of this 
variable ranges from US $25 – $1 million.  Generally total charges in HCUP do not 
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include professional fees and non-covered charges.  If the source provides total charges 
with professional fees, then the professional fees are removed from the charge during HCUP 
processing.  But emergency department charges incurred prior to admission to the hospital 
may have been included in total hospital charges.  Then total hospital costs were 
computed for each discharge record using the Cost-to-charge ratio to convert the charges 
to costs. 
 
Data Analysis 
The data analysis was conducted by using SPSS (version 16.0).  The first eight 
objectives of this study were analyzed using the NIS dataset for the year 2005.  For 
studying trends in LOS, total hospital costs, and the procedures (Objectives 9), datasets 
for 2002-2005 were utilized. 
 
Objective 1: To calculate weighed averages for COPD‐related hospitalizations, 
annual inpatient deaths and mean total charges for the year 2005. 
 Hospital and discharge weights were used to generate national level weighed 
averages for total number of cases with a primary or secondary diagnosis of COPD, and 
annual inpatient deaths and mean total charges and costs due to COPD-related 
hospitalizations. 
 
Objective 2: To describe the COPD‐related hospitalizations in the core in‐patient 
sample from the NIS from HCUP dataset in terms of patient and hospital 
characteristics. 
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A descriptive analysis was conducted where frequencies for each of the patient- 
and hospital-related and other related variables, were analyzed.  Frequencies for LOS, in-
hospital deaths and total hospital charges were also analyzed and reported.  Only those 
patients were included in the analysis, who had a primary diagnosis of COPD. 
 
Objective 3: To compare the differences in the COPD‐related hospital length of stay 
(LOS) by patient and hospital characteristics. 
Means for LOS were compared across each of the patient- and hospital-related 
variables.  Only those patients were included in the analysis, who had a primary diagnosis 
of COPD.  All patient- and hospital-related variables of interest were taken as 
independent variables, whereas LOS was taken as a dependent variable.  For variables 
with more than two categories, one-way ANOVA was conducted to check if the different 
categories of each variable differed significantly among each other.  Those variables 
which were observed to be significant in ANOVA were subjected to Post-hoc Hochberg 
analysis.  The Post-hoc analysis is helpful in isolating exactly where the significant 
differences among variables lie.  For a variable that had two categories (e.g., gender) a t-
test was conducted to see if LOS, total hospital charges, and procedures differed between 
males and females. 
 
Objective 4: To compare the differences in COPD‐related total hospital costs  by 
patient and hospital characteristics. 
Means for total hospital costs were compared across each patient and hospital 
variable.  Only those patients were included in the analysis, who had a primary diagnosis 
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of COPD.   Also here, one-way ANOVA, post-hoc analyses and independent t-test were 
conducted to look for differences among categories. 
 
Objective 5: To compare the differences in COPD‐related in‐hospital deaths by 
patient‐ and hospital‐related characteristics. 
Cross tabulations were conducted to compare proportions of in-hospital deaths 
across the several patient-related and hospital-related variables.  Only those patients were 
included in the analysis, who had a primary diagnosis of COPD. 
 
Objective 6: To identify patient‐ and hospital‐related predictors of COPD‐related 
hospital LOS., total hospital costs and in‐hospital deaths. 
A multiple linear regression model was utilized to achieve this study objective.  
Only those patients were included in the analysis, which had a primary diagnosis of 
COPD.  All patient-related and hospital-related variables were used as independent 
variables to predict LOS.  While conducting the analyses, LOS was taken as the 
dependent variable.  Both Enter and Stepwise methods of multiple linear regressions 
were utilized.  Variables having a significant p-value (defined as p ≤ 0.05) were reported 
as predictors for LOS.  All variables having more than two categories were subject to 
creation of dummy variables.  Hence, dummy variables were created for age, race, 
location, payer information, median household income, and all hospital-related variables. 
Dummy variables are needed as they help in indicating the absence or presence of some 
categorical effect that may shift the outcome of the analyses. 
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Objective 7: To identify patient- and hospital-related predictors of COPD-related total 
hospital costs. 
Similar analysis, as described for objective 6 was conducted, and the dependent 
variable here was total hospital costs. 
 
Objective 8: To identify patient- and hospital-related predictors of COPD-related in-
hospital deaths 
Similar analysis, as described for objective 6 was conducted; however Binary 
logistic regression was used instead of multiple linear regression.  The dependent variable 
here was in-hospital mortality. 
 
Objective 9: To describe the temporal pattern of COPD‐related hospitalization LOS, 
total hospital costs and in‐hospital deaths for 2002, 2003, 2004, and 2005 using the 
core in‐patient sample from the NIS from HCUP dataset. 
Descriptive statistics were conducted to check for the frequencies of LOS, total 
hospital costs and the number of in-hospital deaths for the years 2002, 2003, 2004, and 
2005.   Only those patients were included in the analysis, who had a primary diagnosis of 
COPD.   Means for LOS were reported, and a temporal pattern (trend) if observed, was 
also reported.  Hospital costs were adjusted to the year 2005 (last quarter) levels, using 
the consumer price index for inpatient hospital services that were provided by the Bureau 
of Labor Statistics. 
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CHAPTER FOUR 
RESULTS 
 
In this chapter, results for the study objectives will be presented. 
 
From the NIS dataset for each year, the inpatient discharge-level data representing 
100% of the discharges from a sample of hospitals in participating states was utilized.  
From this main data, only individuals having COPD as primary or secondary diagnosis, 
based on the ICD-9 codes (490.xx-492.xx and 496.xx) were then selected.  For study 
objectives 1 through 8, NIS dataset for year 2005 was utilized, while for study objective 9 
which described the trends, NIS datasets for years 2002-2005 were utilized.  For all the 
analysis, hospitalizations due to COPD as primary diagnosis only were considered; 
except for study objective 1, where hospitalizations due to COPD as secondary diagnosis 
were also considered.  There were 126,504; 127,393; 112,983 and 126,130 
hospitalizations identified with COPD as the primary diagnosis in the datasets for years 
2002, 2003, 2004, and 2005 respectively. 
 
Objective 1: National estimates for hospital LOS, mean total charges, and  
in‐hospital mortality for hospitalizations due to COPD for the year 2005 
Using the 2005 data, descriptive analysis were conducted to determine the 
frequencies of total hospitalizations, mean LOS, mean total charges, in-hospital deaths  
with COPD as both a primary and secondary diagnosis.  Discharge weights were applied 
to derive weighed averages or national estimates.  There were 616,818 estimated 
hospitalizations in the year 2005 with COPD as the primary diagnosis.  Additionally an 
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estimated 1,426,723 hospitalizations were identified, with COPD as the secondary 
diagnosis on record.  Both the mean LOS and the mean total charges and costs were 
higher for records with COPD listed as a secondary diagnosis.  After applying weights, 
the mean LOS and mean total costs for hospitalizations with COPD as primary diagnosis 
were found to be 4.86 and $6,938.55; whereas for hospitalizations with COPD as 
secondary diagnosis, they were 5.03 and $7,636.73, respectively.  There were an 
estimated 12,054 in-hospital deaths due to COPD as primary diagnosis and an estimated 
40,738 in-hospital deaths due to COPD as secondary diagnosis in the year 2005. 
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Table 8. National estimates (Weighed data) of COPD ‐ related hospitalizations:  
NIS 2005 
 
Variable        Diagnosis of COPD 
 
       Primary                         Secondary 
 
 Hospitalizations     616,818#             1,426,723# 
 Deaths       12,054#             40,738# 
 LOS       4.68 ± 3.62*             5.03 ± 4.24* 
 Total hospital charges ($)    17,259.84 ± 21,660.84*                23,450.62 ± 27,784.86* 
 Estimated Costs ($)     6,938.55 ± 7,776.81*                7,636.73 ± 8,250.43* 
 
*Mean ± S.D 
 #Total Number 
LOS = Length of stay 
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Objective 2: Frequency of patient, hospital, and outcome variables 
Using descriptive analysis, frequencies of patient-related, hospital-related, and 
outcome variables for the year 2005 were determined.  Patient variables included age, 
race, gender, payer information, location and median household income.  Hospital 
variables included geographic region, location, and hospital bed-size.  Other variables 
included type of admission (elective vs. non-elective), total number of diagnoses on 
record, total number of procedures on record while outcome variables included length of 
stay, total hospital charges, and in-hospital mortality. 
 
Patient variables 
A descriptive analysis indicated that the study sample consisted predominantly 
females (55.9%), and that the mean age of patients hospitalized with COPD in this 
sample was 68.83 years (S.D. = 13.34).  Caucasians (85.5%) formed a predominant 
section of the patient population, followed by African Americans (7.4%) and Hispanics 
(4.7%).  Other races including Asians or Pacific Islanders and Native Americans, 
together accounted for the least number of hospitalizations due to COPD (2.5%).  The 
patients were mainly located in the large metropolitan areas (44.0%), while only a small 
section (13.1%) located in the non-core areas.  A majority of the patients (33.9%) were in 
the income level group of $1- $36,999 followed by the group with income level $37,000- 
$45,999 (28.3%).  The primary expected payer for most of the patient population was 
Medicare (71.9%) followed by private payers (13.9%) and Medicaid (9.3%). (Refer 
Table 9) 
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Table 9. Patient characteristics of COPD ‐ related hospitalizations: NIS 2005 
 (N = 125,584) 
Patient variables  Level of patient variables            N (%) 
 
Age (years)   0-20             796 (0.6)   
(68.83 ± 13.31)*  21-40          1,851 (1.5) 
               41-64      39,895 (31.8) 
       65-80      59,133 (47.1) 
        81 and above                23,885 (19.0) 
        Total              125,560 (100.0) 
 
Race    Caucasian    76,123 (85.5) 
        African American       6,573 (7.4) 
       Hispanic        4,156 (4.7) 
        Asian                       741 (0.8) 
        Native American          257 (0.3) 
             Other         1,214 (1.4) 
              Total              89,064 (100.0) 
 
Gender   Male                           55,381 (44.1) 
Female    70,140 (55.9) 
Total            125,521 (100.0) 
` 
Payer     Medicare    90,248 (71.9) 
Medicaid      11,653 (9.3) 
Private     17,497 (13.9) 
Self Pay        3,300 (2.6) 
No charge            410 (0.3) 
Other         2,386 (1.9) 
Total             125,494 (100.0) 
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Patient variables  Level of patient variables    N (%) 
 
Patient Location  Large Metropolitan       55,109 (44.0) 
Small Metropolitan       34,865 (27.8) 
Micropolitan                   18,901 (15.1) 
Non-urban                   16,440 (13.1) 
Total      125,315 (100.0) 
 
Income   $1-$36,999         41,500 (33.9) 
$37,000 – $45,999        34,705 (28.3)  
$46,000 – $60,999                                   27,167 (22.2) 
$61,000 +                                          19,116 (15.6) 
Total       122,488 (100.0) 
 
*Mean ± S.D. 
N = Number of hospitalizations at each level 
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Hospital variables  
The hospital located in the Southern region (45.9%) of the U.S., and urban non-
teaching setting (50.9%) accounted for a majority of the hospitalizations.  Very few 
(13.0%) hospitalizations were seen in the Western regions of the U.S.  Also, a majority of 
hospitalizations were observed in hospitals with a large bed size (56.1%), with the least 
number (16.9%) of hospitalizations occurring in hospitals with a small bed size(Refer 
Table 10). 
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Table 10. Hospital characteristics of COPD ‐ related hospitalizations: NIS 2005 
  (N= 125,584) 
 
Hospital variables  Level of hospital variables              N (%) 
 
Geographic Region  Northeast                  22,411 (17.8) 
Midwest                  29,184 (23.2) 
South                   57,697 (45.9) 
West                   16,292 (13.0) 
Total               125,584 (100.0) 
 
Location             Rural                  31,654 (25.2) 
Urban non-teaching                           63,979 (50.9) 
Urban teaching                 29,951 (23.8) 
Total              125,584 (100.0) 
 
Bed-Size   Small                 21,246 (16.9) 
Medium                33,898 (27.0) 
Large                  70,440 (56.1) 
Total             125,584 (100.0) 
 
N = Number of hospitalizations at each level 
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Other procedure and diagnoses‐related variables  
Most (21.8%) hospitalization records had at least 9 diagnoses listed on them, 
while very few (1.3%) had only one diagnoses listed.  The mean number of diagnoses 
listed on record were 7.29 (S.D = 3.14).  In terms of number of procedures on record, 
majority of the records (78%) had no procedures listed, whereas only 11.4% records 
showed at least one procedure to be listed on the record.  Most (89.2%) of the 
hospitalizations were due to non-elective admissions (Refer Table 11). 
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Table 11. Other characteristics of COPD ‐ related hospitalizations: NIS 2005  
(N= 125,584) 
 
Variables              Level of variables                        N (%) 
 
Number of diagnoses  1                    1,589 (1.3) 
on the record   2                    4,428 (3.5) 
(7.29 ± 3.14)*   3                    8,010 (6.4) 
    4                  10,971 (8.7) 
    5                 13,287 (10.6) 
    6                  13,697 (10.9) 
    7                  2,772 (10.2) 
    8                    2,493 (9.9) 
    9                27,391 (21.8) 
              10 and above               20,926 (16.3) 
              Total            125,584 (100.0) 
 
Number of procedures 0     97,910 (78.0) 
on the record   1                14,307 (11.4) 
(0.45 ± 1.14)*   2                    6,212 (4.9) 
    3                    3,319 (2.6) 
    4                    1,622 (1.3) 
    5                        884 (0.7) 
    6                         755 (0.6) 
    7                       213 (0.2) 
    8                       135 (0.1) 
    9                       100 (0.1) 
              10 and above                      127 (0.1) 
              Total            125,584 (100.0) 
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Variables              Level of variables                        N (%) 
 
Type of hospital  Elective                13,271 (10.6)  
admission          Non-elective                         111,995 (89.2) 
              Total                         125,266 (100.0) 
* Mean ± S.D. 
N = Number of hospitalizations at each level 
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Table 12. Top five Secondary Diagnoses listed on records of patient with a Primary 
diagnosis of COPD: NIS 2005 (N= 125,584) 
ICD-9 Code      Disease/ Illness            N (%) 
 
 
428.0         Congestive heart failure, unspecified     15,735 (12.5) 
401.9         Essential hypertension, unspecified       7,863 (6.3) 
427.31         Atrial fibrillation          6,971 (5.6) 
486.0         Pneumonia          4,611 (3.7) 
305.1         Tobacco use disorder               3,626 (2.9)                        
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Table 13. Top five Primary Diagnoses listed on records of patient with a Secondary 
diagnosis of COPD: NIS 2005 (N= 288,992) 
ICD-9 Code      Disease/ Illness          N (%) 
 
 
486.0         Pneumonia              210,669 (14.8) 
428.0         Congestive heart failure, unspecified            119,560 (8.4) 
518.81                     Acute respiratory failure                                                  62,264 (4.4) 
786.59         Chest pain                 29,843 (2.1) 
414.01         Coronary arthrosclerosis                           29,690 (2.1) 
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Outcome variables 
It was seen that LOS for patients hospitalized with COPD ranged from 0-102 
days.  However, to exclude extreme outliers, only those records with LOS ≤ 30 days were 
considered for analysis, and the mean LOS was found to be 4.69 days (S.D. = 3.63) 
(Refer Table 14).  The majority of hospitalizations (52.1%) were for 2-4 days, while only 
8% patients had mean LOS of 10 or more days. 
The total costs for hospitalization for COPD ranged from $29 - $311,599 with a 
mean total charge of $6,939.94 (S.D=7,759.51) for the year 2005.  Around 74.8% of all 
hospitalizations had total charges in the range of $1,000 - $9,999; another 11.3% 
hospitalizations had hospital charges in the range of $10,000 -$19,999, while only 0.5% 
hospitalizations had hospital charges of more than $50,000. 
A total of 2,451 in-hospital deaths due to COPD as primary diagnosis were 
reported in the year 2005 (Refer Table 15).  
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Table 14. Hospital length of stay (LOS), total hospital charges and costs for COPD‐
related hospitalizations: NIS 2005 (N= 125,584) 
 
Outcome variables  Level of outcome variables        N (%) 
 
LOS (days)   0     1,193 (0.9) 
(4.69 ± 3.63)*   1              10,344 (8.2) 
    2            22,189 (17.7) 
    3            23,974 (19.1) 
    4            19,265 (15.3) 
    5             13,758 (11.0) 
    6                  9,699 (7.7) 
    7                7,046 (5.6) 
    8                4,733 (3.8) 
    9                3,280 (2.6) 
              10 & above             10,103 (8.0) 
              Total         125,584 (100.0) 
 
Total hospital charges   0-999                                                     207 (0.2)                      
(dollars)                                   1,000-9,999            53,453 (42.9)  
 (17,383.78 ± 21,719.35)* 10,000-19,999            40,448 (32.5)  
                                                20,000-29,999            14,445 (11.6) 
    30,000-39,999                6,395 (5.1) 
    40,000-49,999                3,409 (2.7) 
    50,000-59,999                1,915 (1.5) 
    60,000-69,999                1,197 (1.0) 
    70,000-79,999                   792 (0.6) 
     80,000-89,999       534 (0.4) 
     90,000-99,999       388 (0.3) 
                        100,000 & above    1,323 (1.1) 
    Total                        125,584 (100) 
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Outcome variables  Level of outcome variables        N (%) 
 
 
Total hospital costs   0-999                                                  1,019 (0.8)                      
(dollars)                                   1,000-9,999            93,897 (74.8)  
 (6,939.94 ± 7,759.51)* 10,000-19,999            14,149 (11.3)  
                                                20,000-29,999              2,876 (2.3) 
    30,000-39,999                 936 (0.7) 
    40,000-49,999                 419 (0.3) 
    50,000-59,999                 195 (0.2) 
    60,000-69,999                 126 (0.1) 
    70,000-79,999                   84 (0.1) 
     80,000-89,999       40 (0.0) 
     90,000-99,999       21 (0.0) 
                        100,000 & above       87 (0.1) 
    Total                      113,849 (100) 
* Mean ± S.D. 
N = Number of hospitalizations at each level 
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Table 15. Deaths during hospitalization in of COPD ‐ related hospitalizations:  
NIS 2005 (N = 125,584) 
Levels of variable ‘Died’                                          N (%) 
 
Died during hospitalization                                    2,451 (2.0) 
Did not die during hospitalization                                             123,092 (98.0) 
Total                                                                    125,543 (100.0) 
  
N = Total Number  
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Objective 3: Differences in length of stay (LOS) by patient‐related and hospital‐related 
variables 
For the year 2005, the differences in LOS were observed for patients with COPD, 
by patients and hospital variables.  Means for LOS were compared across all levels of 
patient- and hospital- related variables. 
 
LOS by patient‐related variables 
The mean LOS was highest for the age group 81 years and above (5.03 days, S.D. 
= 3.70), and lowest for age group 0-20 years (3.04 days, S.D. = 3.08).  African 
Americans and Hispanics had lower LOS (4.77 days, S.D. = 3.88 and 4.73 days, S.D = 
3.75) as compared to Caucasians (4.81 days, S.D. = 3.79).  Females were observed to 
have a longer LOS (4.84 days, S.D. = 3.64) than males (4.51 days, S.D. = 3.60).  The 
patients with Medicare as their primary expected payer had a longer mean LOS (4.89 
days, S.D. = 3.71), followed by those with private payers (4.21 days, S.D. = 3.44), while 
those with no insurance had the lowest mean LOS (3.52 days, S.D. = 3.52 days, S.D. = 
2.72).  Patients living in the large metropolitan had a longer LOS (4.90 days, S.D. = 
3.88), whereas those who lived in the non-core areas had the lowest LOS (4.16 days, S.D. 
= 3.02).  The mean LOS increased with the increasing levels of patient income groups.  
Patients in the income group of $1- $36,999 had a shorter mean LOS (4.53 days, S.D. = 
3.49) than those in the $61,000+ group (5.07 days, S.D. = 3.94). 
A one-way ANOVA was conducted for all the patient variables, except gender. 
All patient variables, except Race were found to be significant (p < 0.050) (Table 16).  To 
further tease out the differences among the levels of the significant patient variables, 
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Post-hoc Hochberg analyses were conducted.  The Post Hoc tables lists the different 
levels of the variables in the first column, and then compares each level to every other 
level to see if they are significantly different.  
The different categories of age were compared, and significant differences were 
seen among all the categories of age (Refer Tables 17, 18).  However, the difference 
between the groups 81+ years and 0-20 years was highest (the LOS was 1.9 days longer 
in the age category 81+ years as compared to those in the group 0-20 years) and the 
difference was least in the groups 81+ years and 65-80 years (the LOS was only 0.16 
days longer in the age category 81+ as compared to those in the group 65-80 years).  
There were significant differences between patients with different Payers, in almost all 
the categories of Payers (Refer Table 19).  The difference was highest between those with 
Medicare and those patients with no insurance, with patients under Medicare observed to 
have longer LOS (1.4 days more than patients with no insurance).  Significant differences 
were also seen among all the categories of patient location, the difference being largest 
between the patient living in the large metropolitan areas and those living in the non-
urban areas (Refer Table 20).  The patients in the large metropolitan areas had a relatively 
longer LOS (0.73 days).  Inpatient median income groups, significant differences in LOS 
were seen across all the levels.  The most difference was seen in patients with income 
$61,000 and above  as compared to those with in the income group $1- $36,999, with the 
former having a longer LOS (0.53 days) than the latter.   
A difference in LOS between males and females was tested using Independent t-
test; and the differences between males and females were found to be found to be 
statistically significant (p<0.05). 
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Table 16. Differences in hospital length of stay (LOS) by patient variables: NIS 2005 
(N= 125,584) 
Patient variables Level of    Mean LOS  S.D. 
   patient variables   (days) 
Age (years)   0- 20     3.04      3.08 
(68.83 ± 13.31)* 21- 40     3.36     2.88 
              41- 64     4.31      3.04  
      65- 80              4.87   3.72 
       81+             5.03   3.74 
       Total      4.69        3.62 
 
Race   Caucasian    4.81           3.79 
       African American   4.77   3.88 
                                    Hispanic                                              4.73                             3.75 
      Other     4.95   4.42 
             Total     4.81   3.75 
 
Gender  Male     4.51       3.60 
Female    4.84           3.64 
 
Payer    Medicare    4.89           3.71 
Medicaid    4.21   3.43 
Private     4.27            3.44 
Self Pay    3.52     2.72 
No charge                                            3.67                             3.00 
Other     4.19   3.21 
              Total      4.69            3.63 
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Patient variables Level of    Mean LOS  S.D. 
   patient variables   (days) 
Patient Location Large Metropolitan   4.90     3.88 
Small Metropolitan   4.71          3.61 
Micropolitan    4.49       3.29 
Non-urban    4.16              3.02 
Total     4.69           3.63 
 
Income ($)  1-36,999    4.53            3.49 
37,000 – 45,999   4.62           3.53 
46,000 – 60,999            4.77         3.71 
61,000 +               5.07           3.94 
   Total     4.69   3.63 
 
* Mean ± S.D. 
LOS = Length of stay 
S.D. = Standard deviation 
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Table 17. Differences between patient variables for length of stay (LOS): NIS 2005 (N= 
125,584) 
 
Patient variables    Test statistics     Sig. (p) 
 
Age      F = 302.426a                 0.000* 
Race      F = 1.991a             0.113 
Payer      F = 228.440a              0.000* 
Patient Location               F = 198.243a                 0.000* 
Income     F = 103.753a                 0.000* 
Gender     T-test = -16.005b                         0.000* 
 
a One-way ANOVA 
b Independent t-test. 
Dependent variable: LOS 
*Significance is at 0.05 level 
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Table 18. Differences within significant patient variable (age) for length of stay (LOS): 
NIS 2005 (N= 125,584) 
 
Age (I)              Age (J)                 Mean Difference          Std. Error Sig. (p) 
 
0-20 years  21-40 years              -0.319   0.153  0.235 
   41-64 years              -1.274   0.129  0.042*  
   65-80 years                  -1.830              0.129  0.000* 
   81+ years              -1.992   0.130  0.000* 
 
21-40 years  0-20 years               0.319                         0.153  0.253 
   41-64 years   -0.955   0.086  0.000*  
   65-80 years        -1.511   0.085  0.000* 
   81+ years   -1.673   0.087    0.000* 
 
41-64 years  0-20 years                1.274   0.129  0.000* 
   21-40 years                    0.955                         0.086             0.000*  
   65-80 years        -0.556   0.023  0.000* 
   81+ years   -0.718   0.030  0.000* 
 
65-80 years  0-20 years               1.830   0.129  0.000* 
                                    21-40 years                   1.511                         0.085                0.000* 
   41-64 years    0.556   0.023   0.000* 
   81+ years   -0.162              0.028   0.000* 
 
81+ years  0-20 years               1.992   0.130  0.000* 
   21-40 years                   1.673                         0.087                0.000* 
              41-64 years    0.718   0.030  0.000*  
   65-80 years         0.162   0.028             0.000* 
     
Post-hoc Hochberg Analysis 
Significant patient variable – Age 
*Significance is at the 0.05 level  
Mean Difference = I – J  
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Table 19. Differences within significant patient variable (payer) for length of stay 
(LOS): NIS 2005 (N= 125,584) 
 
Payer (I)  Payer (J)        Mean Difference          Std. Error Sig. (p) 
 
Medicare  Medicaid                 0.680  0.036  0.000* 
   Private       0.618  0.030  0.000*  
   Self Pay      1.372      0.064  0.000* 
                                    No charge                        1.221                0.179               0.000* 
   Other       0.705  0.075  0.000* 
 
Medicaid  Medicare     -0.680                     0.036  0.000*  
   Private      -0.061            0.043  0.912 
   Self Pay                           0.693                      0.071                0.000* 
                                    No Charge      0.542             0.182   0.000* 
   Other       0.025  0.081   1.000 
 
Private   Medicare                -0.618  0.030   0.000* 
   Medicaid                 0.061  0.043   0.912 
   Self Pay      0.754  0.069   0.000* 
                                    No Charge      0.603                       0.181                0.000* 
   Other                  0.087  0.079   0.990 
 
Self Pay  Medicare                -1.372  0.064   0.000* 
   Medicaid                -0.693  0.071   0.000* 
   Private                 -0.754  0.069   0.000* 
                                    No Charge                      -0.151                      0.189                1.000 
   Other       -0.667  0.097   0.000* 
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Payer (I)  Payer (J)        Mean Difference          Std. Error Sig. (p) 
 
No Charge  Medicare                -1.221  0.179  0.000* 
   Medicaid                -0.542  0.182   0.000* 
   Private                 -0.603             0.181  0.000* 
                                    Self                                  0.151                       0.189               1.000 
   Other                 -0.517  0.193   0.021* 
 
Other   Medicare                -0.705  0.075  0.000* 
   Medicaid                -0.025  0.081  1.000 
   Private      -0.087  0.079  0.990 
   Self Pay      0.667  0.097  0.000* 
   No charge      0.517  0.193    0.021* 
 
Post-hoc Hochberg Analysis 
Significant patient variable – Payer 
*Significance is at the 0.05 level  
Mean Difference = I – J  
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Table 20. Differences within significant patient variable (patient location) for length 
of stay (LOS): NIS 2005 (N= 125,584) 
 
Patient      Patient           Mean Difference        Std. Error         Sig. (p) 
location (I)                     location (J) 
 
Large metropolitan   Small metropolitan           0.187          0.025          0.000* 
     Micropolitan          0.413          0.031          0.000*  
     Non-urban          0.737          0.032          0.000* 
 
Small metropolitan   Large metropolitan          -0.187          0.025          0.000* 
     Micropolitan          0.227          0.033          0.000*  
     Non-urban          0.551          0.034          0.000* 
 
Micropolitan               Large metropolitan          -0.413          0.031           0.000* 
     Small metropolitan          -0.227          0.033           0.000*  
     Non-urban          0.324          0.039           0.000* 
 
Non-urban            Large metropolitan          -0.737         0.032           0.000* 
                                      Small metropolitan          -0.551               0.034                 0.000* 
     Micropolitan         -0.324              0.039           0.000*            
 
Post-hoc Hochberg Analysis 
Significant patient variable – Patient location 
*Significance is at the 0.05 level  
Mean Difference = I – J  
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Table 21. Differences within significant patient variable (median income) for length of 
stay (LOS): NIS 2005 (N= 125,584) 
 
Income (I)     Income (J)             Mean Difference       Std. Error        Sig. (p) 
 
$1- $36,999                   $37,000- $45,999              -0.089          0.026          0.000* 
     $46,000- $60,999          -0.241          0.028          0.000*  
     $61,000 or more          -0.535          0.032          0.000* 
 
$37,000- $45,999          $1- $36,999                         0.089          0.026          0.000* 
     $46,000- $60,999          -0.151          0.029          0.000*  
     $61,000 or more          -0.446          0.033          0.000* 
 
$46,000- $60,999          $1- $36,999                         0.241          0.028           0.000* 
     $37,000- $45,999            0.151          0.029           0.000*  
     $61,000 or more           -0.294          0.034           0.000* 
 
$1- $36,999                   $1- $36,999                         0.535           0.032                  0.000* 
                                      $37,000- $45,999                 0.446          0.033           0.000* 
     $46,000- $60,999            0.294          0.034           0.000*  
   
Post-hoc Hochberg Analysis 
Significant patient variable – Patient location 
*Significance is at the 0.05 level  
Mean Difference = I – J 
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LOS by hospital-related variables 
 The results indicated that LOS was highest in hospitals in the Northeastern region 
(5.42 days, S.D. = 3.98) and lowest in the Western region (4.36 days, S.D. = 3.61) (Refer 
Table 19).  With respect to hospital’s location and teaching status, LOS was high in urban 
areas (4.85 days, S.D. = 3.76 in urban non-teaching and 4.80 days, S.D. = 3.84 in urban 
teaching), as compared to the hospitals in rural areas (4.25 days, S.D. = 3.06). LOS was 
lowest in hospitals with small bed-size (4.39 days, S.D. = 3.68).  
 A one-way ANOVA was conducted to detect differences in LOS across different 
levels of hospital-related variables (Refer Table 23).  All of the hospital-related variables 
were found to be significant (p < 0.050).  Post-hoc Hochberg analyses were further 
conducted, to tease out the differences among the levels of the significant hospital 
variables. 
On comparing the different region categories of hospital, significant differences 
were seen among almost all of the regions (Refer Table 24).  The highest difference was 
seen between the LOS in hospitals in the Western region and hospitals in the 
Northeastern region, and the difference was lowest between the hospital in the Western 
region and those in the Southern region.  Patients from hospitals in the Western region 
had smaller LOS as compared to patients from hospitals in the Northeastern region as 
well as from those in the Southern region (1.06 days shorter, and 0.30 days respectively).  
There were significant differences between patients from hospitals with small, medium, 
and large bed-sizes (Refer Table 25).  The difference was highest between those in 
hospitals with larger bed-size and those patients in hospitals with smaller bed-size.  
Patients from hospitals with larger bed-size had a longer LOS (0.44 days).  In terms of 
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LOS, significant differences were seen across all the three categories of hospital location-
teaching status, the highest difference being between patients from hospitals in the urban 
non-teaching setting and those from hospitals in rural setting (Refer Table 26).  Patients 
from hospitals in the urban settings had a relatively longer LOS than the patients from 
hospitals in the rural setting (0.60 days longer in urban non-teaching and 0.55 days longer 
in urban teaching setting). 
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Table 22. Differences in length of stay (LOS) by hospital variables: NIS 2005  
(N= 125,845) 
 
Hospital variables        Level of        Mean LOS   S.D. 
          hospital variables        (days)  
  
Geographic Region        Northeast    5.42   3.98 
       Midwest    4.38   3.28 
       South    4.66   3.62  
       West    4.36   3.61 
       Total    4.69   3.63 
 
Location                  Rural    4.25     3.06 
          Urban non-teaching  4.85   3.76 
                                           Urban teaching                         4.80   3.84 
          Total    4.69   3.63 
 
Bed Size         Small    4.39   3.68 
       Medium    4.58   3.52 
       Large     4.83   3.67 
          Total    4.69   3.63 
 
LOS = Length of stay 
S.D. = Standard deviation 
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Table 23. Differences between hospital variables for length of stay (LOS): 
 NIS 2005 (N =125,845) 
 
Hospital variables   Test statistics   Sig. (p) 
 
 
Geographic Region   F = 426.15a               0.000* 
Location             F = 311.69a     0.000* 
Bed-Size    F = 138.10a          0.000* 
 
a One-way ANOVA  
b Independent t-test 
Dependent variable: LOS 
*Significance is at the 0.05 level 
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Table 24. Differences within significant hospital variable (region) for length of stay 
(LOS): NIS 2005 (N =125,845) 
 
Region (I)  Region (J)        Mean Difference          Std. Error Sig. (p) 
 
Northeast  Midwest                 1.042  0.032             0.000* 
   South                  0.764  0.028             0.000*  
   West          1.065      0.037  0.000* 
 
Midwest  Northeast                -1.042  0.032  0.000* 
   South                 -0.278  0.026  0.000*  
   West           0.023      0.035  0.986 
 
South     Northeast                -0.764  0.028  0.000* 
                                    Midwest                 0.278  0.026  0.000* 
   West          0.301      0.032  0.000* 
 
West      Northeast                 -1.065  0.037  0.000* 
                                    Midwest                 -0.023  0.035  0.986 
   South                  -0.301  0.032  0.000* 
 
Post-hoc Hochberg Analysis 
Significant patient variable – Geographic location of hospital 
*Significance is at the 0.05 level  
Mean Difference = I – J  
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Table 25. Differences within significant hospital variable (hospital bed size) for length 
of stay (LOS): NIS 2005 (N =125,584) 
 
Hospital  Hospital        Mean Difference          Std. Error Sig. (p) 
bed size (I)                  bed size (J) 
 
Small     Medium               -0.189  0.032  0.000* 
   Large                  -0.436  0.028  0.000*  
  
Medium  Small                    0.189  0.032  0.000* 
   Large                 -0.247  0.024  0.000*  
    
Large     Small                    0.436  0.028  0.000* 
                                    Medium                 0.247  0.024  0.000* 
 
Post-hoc Hochberg Analysis 
Significant patient variable – Hospital bedsize 
*Significance is at the 0.05 level  
Mean Difference = I – J  
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Table 26. Differences within significant hospital variable (location/teaching status) 
for length of stay (LOS): NIS 2005 (N= 125,584) 
 
Hospital         Hospital                             Mean              Std. Error Sig. (p) 
loc-teach (I)            loc-teach (J)                        Difference 
 
Rural            Urban non-teaching            -0.603  0.025  0.000* 
          Urban teaching                    -0.550  0.029  0.000*  
 
Urban           Rural                   0.603  0.025  0.000* 
non-teaching          Urban teaching                     0.053  0.025  0.019* 
 
Urban           Rural                   0.550  0.029  0.000* 
teaching          Urban non-teaching            -0.053  0.025  0.019* 
 
Post-hoc Hochberg Analysis 
Significant patient variable – Hospital bedsize 
*Significance is at the 0.05 level  
Mean Difference = I – J  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
84
Objective 4: Differences in total hospital costs by patient‐related and hospital‐related 
variables 
The overall differences in total hospital costs by patient and hospital variables 
were observed for the year 2005.  This analysis involved comparing mean total hospital 
costs within categories of different patient- and hospital-related variables.  The mean total 
hospital costs were found to be approximately $7,383.66 (S.D. = 8,819.07) per 
hospitalization related to COPD. 
 
Total hospital costs by patient‐related variables 
The results indicated that mean costs per hospitalization increased with age, and 
the hospital costs were highest on an average, for patients in the age group 81+ years 
($7,162.73, S.D. = 7,094.52).  It was observed that Hispanics had the highest per 
hospitalization ($8,600.73, S.D. =9,976.90), followed by African Americans ($7,872.68 , 
S.D. = 8,819).  Caucasians had the least costs per hospitalization ($7,173.65 S.D. = 
8,070.61).  Females ($6,986.66, S.D. =7,651.29) had slightly higher mean costs per 
hospitalization as compared to males ($6,880, S.D. = 7,893.91).  Mean costs per 
hospitalization were found to be the lowest for patients who had no insurance ($4,953.75, 
S.D. = 5,067.98).  The mean costs per hospitalization were higher for patients with 
Medicare and for patients with private insurance ($7,130.74, S.D = 7,772.85 for Medicare 
and $6,710.62, S.D = 8,618.62 for private insurance).  Also, patients who were located in 
non-urban areas had the lowest mean costs compared to patients living in other locations.  
Mean costs per hospitalization were also found to increase, with increasing income levels 
of the patients. 
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A one-way ANOVA was conducted for all the patient variables, except gender.  
All patient level variables were found to be significant (p < 0.050) (Refer Table 28).  
Post-hoc Hochberg analyses were then conducted, to further tease out the differences 
among the levels of the significant patient variables. 
The different categories of age were compared, and significant differences were 
seen among all the categories of age.  Refer Table 29.  However, the difference between 
the groups 81+ years and 0-20 years was highest (the mean costs were $2,245 higher for 
patients, 81+ years of age).  In terms of mean costs, significant differences were seen 
amongst patients of all races (Refer Table 30).  Caucasians had lower mean costs per 
hospitalization as compared to both Hispanics ($1,427 less), as well as African 
Americans ($699 less).  There were significant (p < 0.001) differences between patients 
with different Payers, in almost all categories of Payers (Refer Table 31).  The difference 
was highest between those with Medicare and those patients with no insurance. Patients 
under Medicare were observed to have higher mean costs per hospitalization ($2,176 
more than patients with no insurance).  Least difference was seen between mean costs of 
patients with Medicare and patients with private insurance (mean costs only $420 higher 
for patients with Medicare).  Significant differences (p < 0.001) were also seen among all 
the categories of patient location, the difference being largest between the patient living 
in the large metropolitan areas and those living in the non-urban areas (Refer Table 32).  
The patients in the large metropolitan areas had relatively higher mean costs per 
hospitalization ($10,486.94).  Among the patient median income groups, significant 
differences (p < 0.001) in mean costs were seen across all the levels.  The least difference 
in mean costs was seen in patients in the income group $37,000 - $45,999 and those in 
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the income group $1- $36,999, with the patients in the $37,000 - $45,999 group having 
higher mean costs ($473 more).    
 A difference in total mean costs between males and females was tested using 
Independent t-test; and the differences between males and females were not found to be 
statistically significant (p < 0.05). 
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Table 27. Differences in total hospital costs by patient variables: NIS 2005 
 (N= 125,584) 
 
Patient variables Level of   Mean total            S.D. 
   patient variables  costs ($) per  
       hospitalization 
 Age (years)  0-20    4,917.09              9,775.36 
(68.83 ± 13.31)* 21-40    5,378.72              6,424.86 
41-64    6,617.11              8,141.72 
65-80    7,142.21              7,743.18 
 81+    7,162.73              7,094.52 
   Total    6,939.61              7,758.61 
  
Race                          Caucasian                          7,173.65                      8,070.61                                       
                                  African American   7,872.68              8,819.07 
                                  Hispanic                                     8,600.73                      9,976.90 
                                  Others     8,767.56              10,601.16 
                                  Total     7,309.23              8,273.49 
       
Gender  Male      6,880.97                      7,893.91 
Female     6,986.66               7,651.29 
    
Payer   Medicare     7,130.74               7,772.85 
Medicaid     6,484.98               7,162.72 
Private      6,710.62               8,618.62 
Self Pay     5,325.03               5,416.04 
No charge                                  4,953.75                      5,067.98 
Others                  6,039.56                5,685.31 
  Total       6,940.47                7,759.67 
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Patient variables Level of   Mean total            S.D. 
   patient variables  costs ($) per  
       hospitalization 
           
Patient Location Large Metropolitan      8,035.24              8,983.93 
Small Metropolitan      6,442.47              7,212.26 
Micropolitan       5,950.47              5,824.48 
Non-urban       5,590.29              5,356.69 
   Total        6,936.58              7,707.89 
  
Income  $1- $36,999       6,121.03              6,687.12 
$37,000 – $45,999      6,594.85              7,121.59 
$46,000 – $60,999                      7,447.29              8,229.27                 
$61,000 +       8,649.13              9,597.80 
   Total        6,951.39              7,733.41 
   
* Mean ± S.D. 
S.D. = Standard deviation 
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Table 28. Differences between patient variables for total hospital costs: NIS 2005 (N= 
125,584) 
Patient variables    Test Statistics   Sig. (p) 
Age      F = 57.10a   0.000* 
Race      F = 55.00a   0.000* 
Payer      F = 54.24a   0.000* 
Patient Location    F = 633.88a   0.000* 
Income     F = 483.82a   0.000* 
Gender     T-test = -1.468b  1.43 
 
a One-way ANOVA 
b Independent t-test. 
Dependent variable: Total hospital charges 
*Significance is at 0.05 level 
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Table 29. Differences within significant patient variable (age) for total hospital costs: 
NIS 2005 (N =125,584) 
 
Age (I)              Age (J)                 Mean Difference          Std. Error Sig. (p) 
 
0-20 years  21-40 years            -461.63                       365.84  0.895 
   41-64 years            -1,700.02           316.95  0.000*  
   65-80 years                -2,225.12           316.12             0.000* 
   81+ years            -2,245.64           318.76               0.000* 
 
21-40 years  0-20 years             461.63                       365.84               0.895 
   41-64 years            -1,238.38           191.52             0.000*  
   65-80 years                -1,763.48           190.13             0.000* 
   81+ years            -1,784.01           194.50               0.000* 
 
41-64 years  0-20 years              1,700.02            316.95            0.000* 
   21-40 years                  1,238.38                    191.52              0.000*  
   65-80 years                 -525.09            52.62             0.000* 
   81+ years             -545.62            62.61             0.000* 
 
65-80 years  0-20 years               2,225.12            316.12             0.000* 
                                    21-40 years                   1,763.48                    190.13              0.000* 
   41-64 years    525.09             52.62                0.000* 
   81+ years    -20.52             62.61              1.000 
 
81+ years  0-20 years                2,245.64  318.76              0.000* 
   21-40 years                    1,784.01                   194.50              0.000* 
              41-64 years     545.62  66.70                0.000* 
   65-80 years          20.52                   62.61              1.000 
     
Post-hoc Hochberg Analysis 
Significant patient variable – Age 
*Significance is at the 0.05 level  
Mean Difference = I – J  
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Table 30. Differences within significant patient variable (race) for total hospital costs: 
NIS 2005 (N =125,584) 
 
Race (I)             Race (J)          Mean Difference         Std. Error Sig. (p) 
 
Caucasian     African American             -699.03           116.83  0.010* 
   Hispanic                  -1,427.07           160.61  0.010*  
   Others                               -1,593.90           200.22             0.010* 
    
African American       Caucasian                    699.03                116.83               0.010* 
   Hispanic                   -728.04           193.45              0.011*  
   Others                                -894.87           227.41             0.011* 
 
Hispanic  Caucasian                           1,427.07             160.61               0.010* 
   African American            728.04           193.45  0.011*  
   Others                                -166.83               252.71              0.986 
 
Others    Caucasian                            1,593.90            200.22               0.010* 
   African American             894.87           227.41  0.011*  
   Hispanic                              166.83           252.71              0.986 
     
Post-hoc Hochberg Analysis 
Significant patient variable – Race 
*Significance is at the 0.05 level  
Mean Difference = I – J  
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Table 31. Differences within significant patient variable (payer) for total hospital 
costs: NIS 2005 (N= 125,584) 
 
Payer (I)  Payer (J)        Mean Difference          Std. Error Sig. (p) 
 
Medicare  Medicaid              645.76           79.27            0.000* 
   Private    420.12            67.52            0.000*  
   Self Pay   1,805.71                    150.38             0.000* 
                                    No charge                     2,176.99              426.87              0.000* 
   Other    1,091.18            67.70             0.000* 
 
Medicaid  Medicare   -645.76                     79.27                0.000*  
   Private    -225.63            96.84                0.207 
   Self Pay                         1,159.94                   165.64              0.000* 
                                    No Charge    1,531.23            432.47              0.000* 
   Other     445.42             181.50              0.135 
 
Private   Medicare               -420.12             67.52              0.000* 
   Medicaid                225.63                      96.84                0.207 
   Self Pay     1,385.58             160.34              0.000* 
                                    No Charge     1,756.87                   430.47              0.000* 
   Other                  671.05             176.68              0.000* 
 
Self Pay  Medicare               -1,805.71             150.38              0.000* 
   Medicaid               -1,159.94             165.64              0.000* 
   Private                -1,385.58             160.34              0.000* 
                                    No Charge                       371.28                     450.96              1.000 
   Other      -714.52             221.98              0.000* 
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Payer (I)  Payer (J)        Mean Difference          Std. Error Sig. (p) 
 
No Charge  Medicare               -2,176.99          426.87              0.000* 
   Medicaid               -1,531.23          432.47              0.000* 
   Private                -1,756.87          430.47              0.000*                               
                                     Self                               -371.28                   450.96                1.000 
               Other                -1,085.81           457.03              0.179 
 
Other   Medicare               -1,091.18            67.70               0.000* 
   Medicaid               -445.42                    181.50              0.135 
   Private     -671.05                    176.68              0.000* 
   Self Pay     714.52             221.98              0.000* 
   No charge     1,085.81            457.03     0.179 
 
Post-hoc Hochberg Analysis 
Significant patient variable – Payer 
*Significance is at the 0.05 level  
Mean Difference = I – J  
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Table 32. Differences within significant patient variable (patient location) for total 
hospital costs: NIS 2005 (N= 125,584) 
 
Patient      Patient              Mean Difference      Std. Error         Sig. (p) 
location (I)                     location (J) 
 
Large metropolitan   Small metropolitan         1,592.77          54.87              0.000* 
     Micropolitan        2,084.77             67.31              0.000*  
     Non-urban        2,444.95             71.19              0.000* 
 
Small metropolitan   Large metropolitan         -1,592.77            54.87               0.000* 
     Micropolitan         492.00               71.73               0.000*  
     Non-urban         852.18               75.37               0.000* 
 
Micropolitan               Large metropolitan          -2,084.77           67.31               0.000* 
     Small metropolitan          -492.00              71.73               0.000*  
     Non-urban          360.18               84.86              0.000* 
 
Non-urban            Large metropolitan          -2,444.95            71.19              0.000* 
                                      Small metropolitan          -852.18               75.37              0.000* 
     Micropolitan         -360.18               84.86              0.000*            
 
Post-hoc Hochberg Analysis 
Significant patient variable – Patient location 
*Significance is at the 0.05 level  
Mean Difference = I – J  
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Table 33. Differences within significant patient variable (median income) for total 
hospital costs: NIS 2005 (N= 125,584) 
 
Income (I)     Income (J)             Mean Difference       Std. Error        Sig. (p) 
 
$1- $36,999                   $37,000- $45,999          -473.81                58.74         0.000* 
     $46,000- $60,999      -1,326.25             62.98              0.000*  
     $61,000+         -2,528.09             70.71              0.000* 
 
$37,000- $45,999          $1- $36,999                    473.81                58.74               0.000* 
     $46,000- $60,999      -852.43                64.84               0.000*  
     $61,000+       -2,054.28             72.37               0.000* 
 
$46,000- $60,999          $1- $36,999                     1,326.25             62.98              0.000* 
     $37,000- $45,999        852.43                64.84              0.000*  
     $61,000+             -1,201.84             75.86              0.000* 
 
$61,000+                       $1- $36,999                      2,528.09*           70.71              0.000* 
                                      $37,000- $45,999             2,054.28*            72.37             0.000* 
     $46,000- $60,999        1,201.84*             75.86             0.000*  
   
Post-hoc Hochberg Analysis 
Significant patient variable – Patient location 
*Significance is at the 0.05 level  
Mean Difference = I – J 
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Total hospital costs by hospital-related variables 
The mean costs per hospitalization were found to be the highest for hospitals 
located in the Western region ($9,378.43, S.D. = 12,461.73) and lowest for those located 
in the Southern region ($5,747.31, S.D. = 5,516.07).  Hospitals with teaching status in 
urban areas had higher mean costs per hospitalization ($7,908.41, S.D. =10,355) 
compared to rural hospitals ($5,645.29, S.D. = 5,072.56).  Hospitals with large bed sizes 
had the highest mean costs per hospitalization ($7,272.00, S.D. =8,337.15) than hospitals 
with small or medium bed sizes (Refer Table 34). 
One-way ANOVA were then conducted for all hospital-related variables, which 
indicated that the differences for geographic region, hospital bed size and location 
/teaching status were all statistically significant (Refer Table 35).  A post-hoc Hochberg 
test was conducted to see the differences among these variables. 
On comparing the different region categories of hospital, significant differences 
were seen among almost all four regions (Refer Table 36).  The highest difference was 
seen between the mean costs in hospitals in the Western region and hospitals in the 
Southern region, and the difference was lowest between the hospitals in the Midwestern 
region and those in the Southern region.  The post-hoc tests also showed significance 
difference between hospitals located in urban areas with teaching facilities compared to 
hospitals located in rural areas (p<0.001).  The results showed that teaching hospitals in 
urban areas had higher mean costs per hospitalization ($2,263.11) than hospitals in rural 
areas (Refer Table 37).  There were also significant (p < 0.001) differences in costs for 
patients from hospitals with small, medium, and large bed-sizes (Refer Table 38).  The 
difference was highest between those in hospitals with larger bed-size and those patients 
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in hospitals with smaller bed-size.  Patients from hospitals with larger bed-size had higher 
mean costs ($1,088.37 more). 
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Table 34. Differences in total hospital costs by hospital variables: NIS 2005  
(N= 125,845) 
 
Hospital variables  Level of  Mean total                S.D 
    hospital variables costs ($) per  
                                                                                     hospitalization 
Geographic Region  Northeast  8,649.14            8,690.17 
Midwest  6,270.35            6,201.74 
South   5,747.31            5,516.07 
West   9,378.43            12,461.73 
Total   6,939.94            7,759.51 
 
Location   Rural   5,645.29             5,072.56 
Urban non-teaching   7,152.18             7,394.35 
    Urban teaching 7,908.41             10,355.40 
    Total   6,939.94             7,759.51  
 
Bed-size   Small   6,183.63              6,560.40 
Medium  6,716.97              7,126.57 
Large   7,272.00              8,337.15 
    Total   6,939.94              7,759.51 
 
S.D. = Standard deviation 
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Table 35. Differences between significant hospital variables for total hospital costs: 
NIS 2005 (N= 125,845) 
Hospital variables    Test Statistics   Sig. (p) 
Geographic Region    F = 1355.46a              0.000* 
Location / Teaching status   F = 647.23a   0.000* 
Bed-size     F = 163.22a   0.000* 
 
a One-way ANOVA  
Dependent variable: Total hospital charges 
*Significance is at the 0.05 level 
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Table 36. Differences within significant hospital variable (region) for total hospital 
costs: NIS 2005 (N= 125,845) 
 
Region (I)  Region (J)        Mean Difference          Std. Error Sig. (p) 
 
Northeast  Midwest             2,378.79  67.76            0.000*  
   South              2,901.83  61.89            0.000*  
   West                -729.28      79.96            0.000* 
 
Midwest  Northeast            -2,378.79  67.76            0.000* 
   South              523.04    56.85            0.000*  
   West                -3,108.07     76.12            0.000* 
 
South     Northeast             -2,901.83  61.89             0.000* 
                                    Midwest             -523.04  56.85             0.000* 
   West                -3,631.11    70.96             0.000* 
 
West      Northeast             729.28   79.96            0.000* 
                                    Midwest             3,108.07  76.12            0.000* 
   South              3,631.11  70.95            0.000* 
 
Post-hoc Hochberg Analysis 
Significant patient variable – Geographic location of hospital 
*Significance is at the 0.05 level  
Mean Difference = I – J  
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Table 37. Differences within significant hospital variable (hospital location‐teaching) 
for total hospital costs: NIS 2005 (N= 125,845) 
 
Hospital         Hospital                              Mean              Std. Error Sig. (p) 
loc-teach (I)            loc-teach (J)                         Difference 
 
Rural            Urban non-teaching            -1,506.88  55.25  0.000* 
          Urban teaching                    -2,263.11  65.16  0.000*  
 
Urban           Rural                   1,506.88  55.25  0.000* 
non-teaching          Urban teaching                     -756.23  57.08  0.000* 
 
Urban           Rural                    2,263.11  65.16  0.000* 
teaching          Urban non-teaching              756.23  57.08  0.000* 
 
Post-hoc Hochberg Analysis 
Significant patient variable – Hospital bed size 
*Significance is at the 0.05 level  
Mean Difference = I – J  
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Table 38. Differences within significant hospital variable (hospital bed‐size) for total 
hospital costs: NIS 2005 (N= 125,845) 
 
Hospital  Hospital        Mean Difference          Std. Error Sig. (p) 
bed size (I)                  bed size (J) 
 
Small     Medium           -533.33    71.38             0.000* 
   Large              -1,088.37  63.67             0.000*  
  
Medium  Small              533.33              71.38             0.000* 
   Large           -555.03              53.95             0.000*  
    
Large     Small               1088.37  63.67              0.000* 
                                    Medium            555.03    53.95              0.000* 
 
Post-hoc Hochberg Analysis 
Significant patient variable – Hospital bedsize 
*Significance is at the 0.05 level  
Mean Difference = I – J 
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Objective 5: Differences in in‐hospital mortality by patient‐related and hospital‐
related variables 
The overall differences in in-hospital mortality by patient and hospital variables 
were observed for the year 2005 using Cross tabulations. A total of 2,451 (2.0%) in-
hospital deaths were observed in the sample for the year 2005, with COPD as a primary 
diagnosis on record. 
 
In‐hospital deaths by patient‐related variables 
The proportion of in-hospital deaths as a hospitalization outcome increased with 
increasing age, and was higher for males (2.2%) as compared to females (1.8%).  Results 
indicated that proportion of in-hospital deaths was highest (3.2%) for patients in the age 
group 81+ years, and lowest (0.1%) for patients in the age group 21-40 years.  Caucasians 
(2.2%) were seen to have a higher proportion of in-hospital deaths as compared to 
African Americans (1.3%) and Hispanics (1.7%).  Higher proportion of in-hospital 
mortality was observed in patients with Medicare (2.1%) and those with private insurance 
(2%).  Patients who were located in non-urban areas reported lower (1.7%) proportions of 
in-hospital mortality, as compared to patients living in other locations (Table 39). 
 
In‐hospital deaths by hospital‐related variables 
 The proportion of in-hospital deaths was observed to be relatively higher (2.6%) 
in the hospitals from Northeastern part of the US.  More in-hospital deaths were reported 
in the hospitals in the urban setting, and also in hospitals with large bed-sizes (Table 40).  
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Table 39. Differences in in‐hospital mortality by patient variables: NIS 2005 (N =125,845) 
Patient variables Level of              Did not die                         Died                           Total 
   patient variables   
 
Age (years)  0-20      794 (99.7)                          2 (0.3)                 796 
   21-40    1,849 (99.9)                          2 (0.1)               1,851 
41-64             39,559 (99.2)                      327 (0.8)             39,886 
65-80             57,754 (97.7)                   1,359 (2.3)             59,113 
 81+             23,112 (96.8)                         761 (3.2)             23,873 
 Total           123,068 (98.0)                    2451 (2.0)           125,519 
 
Race   Caucasian            74,448 (97.8)        1,642 (2.2)            76,090 
                                    African American  6,487 (98.7)             85 (1.3)              6,572 
                                    Hispanic                                  4,086 (98.3)             69 (1.7)              4,155 
 Others     2,169 (98.1)             42 (1.9)              2,211 
 Total              87,190 (97.9)                   1,838 (2.1)             89,028 
        
Gender  Male              54,143 (97.8)         1,217 (2.2)            55,360 
Female             68,886 (98.2)        1,234 (1.8)            70,120 
  Total             123,029 (98.0)        2,451 (2.0)          125,480 
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Patient variables Level of variable     Did not die                              Died                           Total 
      
Payer   Medicare       88,282 (97.9)  1,934 (2.1)    90,216 
Medicaid       11,570 (99.3)       82 (0.7)    11,652 
Private        17,140 (98.0)     352 (2.0)    17,492 
Self Pay         3,277 (99.3)       23 (0.7)      3,300 
No charge                                         407 (99.3)         3 (0.7)         410 
Others                      2,330 (97.7)       55 (2.3)      2,385 
  Total       123,006 (98.0)             2,449 (2.0)              125,455 
 
Patient Location Large Metropolitan       53,988 (98.0)             1,097 (2.0)    55,085 
Small Metropolitan       34,136 (97.9)     719 (2.1)    34,855 
Micropolitan        18,545 (98.1)     354 (1.9)    18,899 
Non-urban        16,161 (98.3)     279 (1.7)    16,440 
   Total       122,830 (98.0)              2,449 (2.0)             125,279 
  
Income  $1- $36,999        40,793 (98.3)                699 (1.7)    41,492 
$37,000 – $45,999       34,033 (98.1)     667 (1.9)    34,700 
$46,000 – $60,999                       26,555 (97.8)     597 (2.2)    27,152 
$61,000 +        18,663 (97.7)     446 (2.3)    19,109 
   Total       120,044 (98.0)             2,409 (2.0)             122,453 
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Table 40. Differences in in‐hospital mortality by hospital variables: NIS 2005 (N= 125,845) 
 
Patient variables             Level of                Did not die                           Died                            Total 
            patient variables   
 
Geographic Region  Northeast       21,805 (97.4)      590 (2.6)                 22,395 
Midwest        28,617 (98.1)                 553 (1.9)                29,170 
South         56,738 (98.3)     958 (1.7)                57,696 
West         15,932 (97.9)      350 (2.1)                 16,282 
Total             123,092 (98.0)           2,451 (2.0)               125,543 
 
Location   Rural         31,096 (98.2)      557 (1.8)       31,653 
Urban non-teaching          62,688 (98.0)           1,262 (2.0)       63,950 
    Urban teaching       29,308 (97.9)      632 (2.1)      29,940 
    Total              123,092 (98.0)           2,451 (2.0)    125,543 
 
Bed-size   Small          20,830 (98.1)      404 (1.9)      21,234 
Medium        33,294 (98.2)       599 (1.8)      33,893 
Large          68,968 (97.9)            1,448 (2.1)       70,416 
    Total              123,092 (98.0)            2,451 (2.0)    125,543
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Objective 6: Patient‐ and hospital‐related predictors of hospital LOS . 
To assess the predictors of LOS, multiple regression analyses were conducted, 
and dummy variables were used for variables with more than two levels.  
 
Predictors of length of stay (LOS) 
 A multiple linear regression was conducted to find the variables that predicted 
LOS in hospitalized patients with COPD. An ‘Enter’ regression was conducted to 
determine significant predictors and further a ‘Stepwise’ regression  was conducted to 
find out the predictors, which contributed most to the variance in LOS (Refer Tables 41, 
42). 
 
 The regression analysis conducted by the Enter method found most variables to be 
significant predictors for LOS (i.e. had a p-value of ≤ 0.05). The variables not found to be 
significant were the race African American, the ‘other’ category of health insurance, the 
micropolitan patient location, the $61,000+ income group, and the urban-teaching 
hospital setting.  
 Males had a smaller (0.3 days less) LOS as compared to females. Both patients 
with no health insurance (0.5 days less), patients with private insurance had a smaller 
LOS (0.5 days, and 0.2 days less) as compared to those with Medicare in the regression 
model. Also patients from the Western and Midwestern region had LOS smaller than 
those from the Southern region (0.7days less and 0.5 days less respectively). Patients 
from small bed size hospitals had 0.3 days smaller LOS than from large bed size 
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hospitals. Patients who had Elective type of hospital admission had a shorter LOS stay 
(0.5 days less) in the regression model.  
The results for Stepwise method of multiple linear regression analysis for hospital 
LOS of COPD patients are shown in Table 41. Only significant variables (p< 0.001) 
entered the model, and the final model (Step 3) accounted for 19.3% of the variance in 
hospital LOS, where Number of procedures accounted for most of the variance (13.5%). 
The other significant predictors (sequentially in the order of inclusion in the model) that 
entered in this model were Number of diagnoses, Midwestern region, Western region, 
Gender (female), Elective type of hospital admission, Urban non-teaching hospital 
setting, patients with no insurance or private insurance, patients with Medicaid, North 
eastern region, small and medium bed size hospital setting, and small metropolitan area. 
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Table 41. Factors associated with length of stay (LOS) for COPD – related 
hospitalizations: NIS 2005(N= 125,845) {Enter Method} 
 
        Model         B        SE          t                Sig.  
Variables         Levels 
 
 
Age             -                  0.015      0.001   18.01            0.000* 
  
Race        Caucasian†  
      African American     0.020      0.042    0.462           0.644 
        Hispanic              0.149      0.052    2.844           0.004* 
        Others      0.369      0.070    5.252           0.000* 
 
Gender       Female† 
                              Male       -0.328                0.19              -0.045          0.000*    
 
Payer        Medicare†                            
                              Medicaid                  -0.151       0.036    -4.148          0.000* 
        Pvt. Insurance      -0.209       0.030    -7.069          0.000* 
        Self-pay             -0.564       0.060    -9.390          0.000* 
        Other       -0.126       0.069    -1.841          0.066 
 
Location        Large Metro† 
                               Small Metro       -0.149       0.023    -6.353           0.000* 
         Micropolitan       -0.085       0.047    -1.796           0.073 
         Non-Core             -0.174              0.048    -3.623           0.000* 
 
Income       $1,000 - $36,999† 
                              $37,000 – $45,999       -0.075        0.025    -0.009           0.002* 
                              $45,000 – $60,999       -0.077        0.028    -0.009           0.006*      
                              $61,000 +          0.002        0.033      0.065          0.948 
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        Model            B         SE        t                 Sig.  
Variables         Levels 
 
Geog. Region       South† 
                              Northeast                    0.192       0.028    6.984            0.000* 
        Midwest        -0.490       0.024   -20.220 0.000* 
        West        -0.743       0.030   -24.972 0.000* 
 
Location/               Rural†            
Teaching       Urban non-teaching     0.220       0.044     5.012           0.000* 
        Urban teaching                  -0.041             0.046            -0.895           0.371 
 
Bed-size        Large† 
       Small          -0.293       0.026    -11.132         0.000* 
         Medium          -0.222       0.022    -10.140         0.000* 
 
Admission              Non-elective† 
Type                       Elective                  -0.548            0.030           -18.120         0.000* 
 
Number of                    -                                0.220              0.003      71.149         0.000* 
diagnoses 
 
Number of                    -             1.041         0.008            124.649       0.000* 
procedures 
           
Multiple Linear Regression Analysis – Enter Method, all variables entered. 
Dependent variable: LOS 
*Significance is at 0.05 level 
†Reference category  
B = Regression Coefficient; SE = Standard Error of the regression coefficients; t = t-test (ratio of the 
sample regression coefficient B to its standard error) 
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Table 42. Factors associated with length of stay (LOS) for COPD – related 
hospitalizations: NIS 2005 (N= 125,845) {Stepwise Method} 
 
                            B     SE              β           R2                
 
Step 1 
    Constant      4.159               0.010                            0.135 
    Number of procedures    1.168               0.008              0.367     
Step 2 
    Constant      2.494               0.024             0.178 
    Number of procedures    1.031               0.008              0.325     
    Number of diagnoses    0.237               0.003              0.205 
Step 3 
     Constant      3.517               0.041              0.193 
     Number of procedures    1.035               0.008              0.326     
     Number of diagnoses    0.226               0.003              0.195 
     Midwest region    -0.499               0.024             -0.058 
     West region     -0.715   0.029             -0.066 
     Gender (Female)     -0.333   0.019             -0.046 
     Elective admission     -0.534   0.030             -0.046 
     Urban non-teaching setting    0.272   0.020              0.037 
     Payer- Self pay     -0.836   0.058             -0.037 
     Payer- Private and HMO    -0.420   0.027             -0.040 
     Payer-Medicaid     -0.442   0.032             -0.035 
     Northeast region      0.231   0.027              0.024 
     Small bed-size     -0.289   0.026             -0.030 
     Medium bed-size     -0.221   0.022             -0.027 
     Small metropolitan areas    -0.163   0.022             -0.020 
 
Multiple Linear Regression Analysis – Stepwise Method, only significant variables entered. 
Dependent variable: LOS 
Significance is at 0.05 level 
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B = Regression Coefficient; SE = Standard Error of the regression coefficients; β = Standardised regression 
coefficient; R2 = Adjusted R2 
Reference category = Race (Caucasians). Gender (Female), Payer (Medicare), Location (Large metro), 
Income ($1-$35,999), Geographic region (South), Location/Teaching Status (Urban Teaching), Bed-size 
(Large) 
ΔR2 Step 1= 0.135 
ΔR2 Step 2= 0.043 
ΔR2 Step 3= 0.015 
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Objective 7: Patient‐ and hospital‐related predictors of total hospital costs. 
To assess the predictors of total hospital costs, multiple regression analyses were 
conducted, and dummy variables were used for variables with more than two levels.  
 
 Predictors of total hospital costs 
A multiple linear regression was conducted to test the variables that predict total 
hospital charges. Just like for LOS, an ‘Enter’ regression to determine significant 
predictors and further a ‘Stepwise’ regression  was conducted to find out the predictors, 
which contributed most to the variance in total hospital charges. Refer tables 43, 44. 
  
 By using Enter method in multiple linear regression analysis, it was found that 
most patient-related and all hospital- related variables were significant predictors for total 
hospital costs (i.e. had a p-value of ≤ 0.05). The variables not found to be significant were 
no health insurance and patient income groups $37,000 - $45,999, and age at admission  
 
 Hispanics had a total of $910 higher charges per hospitalization than Caucasians 
(reference group in dummy variables). Males had $170.89 lesser costs per hospitalization 
than females (reference group in dummy variables). Those with no insurance had $617.57 
lesser costs per hospitalization than those with Medicare (reference group in dummy 
variables), also patients who lived in the non-urban areas had costs per hospitalization 
$623.68 than those who lived in the large metropolitan areas (reference group in dummy 
variables). Hospitals in the Western region had a total of $2,426 higher charges per 
hospitalization than hospitals in the Southern region (reference group in dummy 
variables), and hospitals in the urban non-teaching setting had $455.06 higher charges 
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than hospitals in rural setting. Patients who had elective type of hospital admission had 
$394.74 lesser charges per hospitalization than those who had a non-elective type of 
hospital admission (reference group in dummy variables). 
  
Table 43 shows the Stepwise method of multiple linear regression analysis for 
total hospital costs of patients with COPD. Only significant variables (p< 0.001) entered 
the model, and the final model (Step 3) accounted for 29.8% of the variance in total 
hospital costs, with Number of procedures and Number of diagnosis again accounting for 
most of the variance (27.2%). The other significant predictors (sequentially in the order 
of inclusion in the model) that entered in this model were Western region, Northeastern 
region, patients in the income group $61,000+, Micropolitan areas of patient location,  
small and medium hospital bed size, the Hispanic race/ethnicity category, African 
American race/ethnicity category, Elective type of hospital admission, and urban hospital 
setting. 
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Table 43. Factors associated with total hospital costs for COPD – related 
hospitalizations: NIS 2005(N= 125,845) {Enter Method} 
               Model          B         SE          t               Sig.  
Variables         Levels 
 
Age             -                -1.455     1.805    -0.806           0.420 
  
Race      Caucasian† 
    African American     691.915      93.078     7.434           0.000* 
      Hispanic              910.106      101.658    -1.885           0.059 
      Others      934.764            112.981         -1.114           0.034* 
 
Gender      Female† 
                             Male      170.890      39.023      4.379           0.000* 
 
Payer       Medicare† 
                             Medicaid                 -246.709       75.745      -3.257         0.001* 
        Pvt. Insurance     -188.896       62.556      -3.020         0.003* 
        Self-pay            -602.529       131.655          -4.577         0.000* 
                              No charge                  -617.577            360.965          -1.711         0.087 
        Other       -269.582       143.007       -1.885         0.059 
 
Location        Large Metro† 
                               Small Metro       -1,151.927         49.247      -23.391       0.000* 
         Micropolitan       -1,147.991         99.398         -11.549        0.000* 
         Non-Core                   -623.686         101.726      -6.131         0.000* 
 
Income       $1,000 - $36,999† 
                              $37,000 – $45,999        85.006       51.670       1.645          0.080 
                              $46,000 – $60,999        361.578       58.543        6.176         0.000*      
                              $61,000 +          950.646       69.266       13.724        0.000* 
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        Model            B        SE      t                Sig.  
Variables         Levels 
 
Geog. Region         South† 
                                Northeast                    971.118       57.433    16.935          0.001* 
          Midwest          -237.744       50.360    -4.721           0.000* 
          West          2426.448       63.035    38.494           0.000* 
 
Location/                 Rural† 
Teaching         Urban teaching          -276.762        97.307     -2.844          0.004* 
          Urban non-teaching     -455.067        92.592     -4.915          0.000* 
 
Bed-size         Large† 
        Small          -643.122          55.191         -11.653        0.000* 
          Medium          -523.436          46.145      -11.343       0.000* 
 
Admission              Elective 
Type                       Non-elective         -394.740          65.222           6.052         0.000* 
 
Number of                    -                               432.029           6.585        65.606       0.000* 
diagnoses 
 
Number of                    -            2,974.112       17.403          170.895      0.000* 
procedures 
          
Multiple Linear Regression Analysis – Enter Method, all variables entered. 
Dependent variable: Total hospital costs 
*Significance is at 0.05 level 
†Reference category  
B = Regression Coefficient; SE = Standard Error of the regression coefficients; t = t-test (ratio of the 
sample regression coefficient B to its standard error) 
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Table 44. Factors associated with total hospital costs for COPD – related 
hospitalizations: NIS 2005 (N= 125,845) {Stepwise Method} 
 
                              B     SE                 β             R2                
 
 
Step 1 
    Constant      5,429.07            21.62                          0.240 
    Number of procedures    3,295.91            17.40   0.490     
Step 2 
    Constant      2,238.64           50.11                        0.272 
    Number of procedures    3,040.04           17.42    0.452     
    Number of diagnoses    454.61              6.437   0.182 
Step 3 
     Constant      2,3298.42   77.43                        0.298 
     Number of procedures    2968.30           17.32               0.400     
     Number of diagnoses    437.22              6.45               0.146 
     West region     2434.68            62.84    0.116 
     Northeast region      984.76    56.88   -0.067 
     Small metropolitan areas                 -1137.81           49.16 
     $61,000 +                 914.66              62.38               0.029 
     Micropolitan               -928.43    68.16    -0.070 
     Small bed-size      -633.80    49.29   -0.064 
     Race- Hispanic     876.26    98.56    0.044 
     Medium bed-size    -530.24    24.40              -0.037 
     Race- African American    653.91    41.35    0.030 
     $46,000- $60,999     318.21    40.94    0.022 
     Non-elective admission   -411.06    71.44              -0.021 
     Male sex                                  174.12    24.29               0.067 
     Non core areas                -426.60    61.60    0.045 
     Midwest region     -229.00    18.01   -0.013 
     Urban non teaching setting   -212.36            -14.03   -4.573    
Multiple Linear Regression Analysis – Stepwise Method, only significant variables entered. 
Dependent variable: Total hospital costs 
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Significance is at 0.05 level 
 
B = Regression Coefficient; SE = Standard Error of the regression coefficients; β = Standardised regression 
coefficient; R2 = Adjusted R2 
Reference category = Race (Caucasians). Gender (Female), Payer (Medicare), Location (Large metro), 
Income ($1-$35,999), Geographic region (South), Location/Teaching Status (Urban Teaching), Bed-size 
(Large) 
ΔR2 Step 1= 0.240 
ΔR2 Step 2= 0.272 
ΔR2 Step 3= 0.298 
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Objective 8: Patient‐ and hospital‐related predictors of in‐hospital mortality. 
To assess the predictors of in-hospital mortality, binary logistic regression 
analyses were conducted, and dummy variables were used for variables with more than 
two levels.  
 
 Predictors of length of in-hospital mortality 
The Forward Wald method was used, and only significant predictors entered the 
model, and the final model (Step 3) accounted for 22% of the variance in in-hospital 
mortality, with Number of procedures alone accounting for most of the variance (14%). 
The other significant predictors (sequentially in the order of inclusion in the model) that 
entered in this model were  Age, Number of diagnoses, Private payer, non-elective type 
of hospital admission, gender, the race African American, and Medium bed-size hospital 
setting. 
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Table 45. Factors associated with in‐hospital mortality for COPD – related 
hospitalizations: NIS 2005 (N= 125,845) {Forward Wald Method} 
 
                              B     SE              Wald             R2                
 
 
Step 1 
    Constant      -4.301             0.025              30340.15  
    Number of procedures     0.423             0.009              2307.32  0.014 
   
Step 2 
     Constant       -8.527   0.177  2311.37           
     Number of procedures      0.403             0.010             1750.80   0.022 
     Age         0.054             0.002              651.85 
     Number of diagnoses      0.068             0.006              124.93 
     Payer- Private and HMO      0.631     0.064    96.70 
     Non elective admission                -0.423             0.061              47.90 
     Payer-Other                  0.745   0.143               27.14 
     Gender (Male)                     0.229   0.042               29.49 
     Race- African American                   -0.286   0.114               6.277 
     Medium bed-size         -0.121   0.049               6.090 
      
Logistic Regression Analysis – Forward Wald Method, only significant variables entered. 
Dependent variable: In-hospital mortality 
Significance is at 0.05 level 
 
B = Regression Coefficient; SE = Standard Error of the regression coefficients; β = Standardised regression 
coefficient; R2 = Adjusted R2 
Reference category = Race (Caucasians). Gender (Female), Payer (Medicare), Location (Large metro), 
Income ($1-$35,999), Geographic region (South), Location/Teaching Status (Urban Teaching), Bed-size 
(Large) 
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Objective 9: Trends in hospital LOS, total hospital charges, and in‐hospital deaths for 
years 2002‐2005 
Descriptive analysis was conducted using NIS datasets for the years 2002-2005 to 
determine trends in hospital LOS, total hospital charges and number of in-hospital deaths. 
The number of hospitalized cases with COPD listed as the primary diagnosis was  
126,504 cases, 127,393 cases, 112,983 cases, and 126,130 cases in the year 2005 in the 
year 2002, 2003, 2004 and 2005 respectively. 
 The results also showed a decreasing trend in the hospital LOS, it being highest 
for the year 2002 (4.88 days, S.D = 3.76). Refer Table 46, and highest for the year 2005 
(4.69 days, S.D = 3.63).  The charges however showed an increasing trend. The total 
hospital charges per hospitalization were highest for the year 2005 .  In terms of in-
hospital mortality, there was a decreasing trend, which appeared to level off towards the 
end. 
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Table 46. Trends in hospital length of stay (LOS) and total hospital costs (THC): NIS, 
2002‐2005  
 
Variables             Years 
      2002        2003          2004                     2005 
 
N      126,504        127,393           112,983               126,130 
Mean LOS (days)    4.88           4.76            4.71            4.69 
Mean THC ($)*              6,958                   7,206                  7,293                    7,383          
Deaths      3,355                    3,052            2,570     2,587 
 
N = Number of hospitalizations in each year 
THC= Total hospital costs 
* Inflated costs (2005 values) 
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Figure 2: Trends in hospital LOS, NIS 2002‐2005. 
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Figure 3: Trends in mean total hospital costs (Inflated, 2005 values),               NIS 2002‐
2005. 
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Figure 4: Trends in in‐hospital mortality, NIS 2002‐2005. 
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CHAPTER FIVE 
DISCUSSION AND CONCLUSIONS 
 
 
In this chapter, implications and study limitations will be presented. 
 
Chronic Obstructive Pulmonary Disease (COPD) affects nearly 12 million 
individuals in the United States.  In this study, the Nationwide Inpatient Sample (NIS) 
dataset from the Healthcare Cost Utilization Project (HCUP) database was used to study 
the various patient- and hospital-related characteristics of patients hospitalized with 
COPD, for the years 2002, 2003, 2004, and 2005.  Important outcome variables such as 
hospital length of stay, total hospital costs, and in-hospital mortality; and the factors 
associated with these outcomes were studied in hospitalized cases with a primary or 
secondary (listed second on the discharge records) diagnosis of COPD  
 
For the year 2005, the number of hospitalized cases with COPD listed as the 
secondary cause of diagnosis  (national estimate 1,426,723) were found to be more than 
twice the number of hospitalized cases with COPD listed as the primary diagnoses           
(national estimate 616,818).  In another study, McGhan et al. (2007) found that patients 
were more than four times likely to have a prior “non-COPD” hospitalization than a prior 
COPD hospitalization; which highlights the high prevalence of co-morbid conditions in 
patients with COPD.30   It has been reported that even in patients with severe COPD, a 
large proportion of patients are admitted to the hospital for other comorbidities. Thus, 
COPD is seldom labeled as a secondary diagnosis,  and non-respiratory diseases account 
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for > 50% of the underlying causes of death in COPD.17, 41, 42   Consistent with other 
studies, the most prevalent co morbid  conditions in patients with COPD were 
pneumonia, hypertension, congestive heart failure, cardiac arrhythmia, and peripheral 
vascular disease.17, 41    In our study, the number of in-hospital deaths was more than three 
times in cases with COPD listed as the secondary diagnosis, as compared to the number 
of deaths in cases with COPD listed as the primary diagnosis.  Thus, it is likely that the 
burden of disease associated with COPD is substantially underestimated. Some of the 
other factors accounting for such an underestimation include reduction in the incidence of 
COPD exacerbations requiring hospitalization (which would otherwise be labeled as 
primary discharge diagnosis), due to outpatient treatment.43  
 
Our findings from the 2005 NIS data showed that patients with COPD in the age 
group 65-80 years had the highest number of hospitalizations (47.1%), with the mean age 
being 68.83 years.  This finding is similar to the results of a study by McGhan and 
colleagues (2007), where the mean age of patients with COPD was found to be 68.81 
years.30  Also, the proportion of in-hospital deaths was highest in the age group 65 and 
above.  These findings are in support of the natural history of COPD among smokers, 
which describes that smoking behaviors start during youth, lung function decline 
becomes apparent when smokers reach age 40-50 years, hospitalizations begin when 
smokers reach age 50-69, and deaths occur when they reach age 60-79.44   It was seen that 
patients with COPD, 65 years and older accounted for 66.1% of the hospitalizations.  
This is in accordance with the fact that patients under Medicare accounted for 71.9% of 
hospitalizations.  
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The results showed that the number of hospitalized cases for COPD were higher 
in females, as compared to males.  This is consistent with results from the study using the 
2003 National Health Interview Survey (NHIS), which indicated higher rates of 
combined chronic bronchitis and emphysema in females than males.12  Han MK and 
colleagues (2007) suggest that COPD prevalence in women is likely to increase now, as 
women are living longer, there is increased tobacco use in women and they are exposed 
to the same workplace risks as men.12  Also, some studies hypothesize that females may 
be at greater risk of smoking induced lung function impairment for the same level of 
tobacco exposure.12  Studies have demonstrated that in terms of impact on secondary care 
COPD is a disease of the elderly and is becoming more common in women.31 
 
COPD is considered to be disease of the “Caucasians”, and studies show that the 
prevalence of COPD remains higher in Caucasians than in African Americans.45  Our 
study results too showed the same pattern with Caucasians being most commonly 
affected (85.5%) followed by African americans (7.4%) and Hispanics (4.7%).   
Patients with the lowest median household income had more than twice the 
number of hospitalizations as compared with those with highest income (33.9% vs 
15.6%).  Buist et al. (2007) reported that COPD is causally associated with cigarette 
smoking and with adverse working conditions, both of which, in turn manifest a strong 
socio-economic status (SES) gradients.46   Blanc et al. (2008) also observed that lower 
SES was strongly linked to decreased odds of using tiotropium, a COPD medication 
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introduced in recent years; and suggested that health care access and such SES gradients 
in medication use represent a potential source of health disparities.47  
 
Our study results showed that almost 46% of all the hospitalizations due to COPD 
were reported in hospitals in the Southern region. This is in accordance with the report on 
COPD mortality rates (1990-1997), funded by the Appalachian region commission; 
which showed that distinct geographic patterns are evident in the distribution of COPD 
death rates.48  The authors reported that high death rates from COPD are predominant in 
the regions of Kentucky, West Virginia, Georgia, and Alabama; and all these states were 
categorized as Southern region in the NIS dataset used in our study.  
 
 Our study results also showed that patients with COPD were more likely to be 
admitted to large and urban setting hospitals.  Increased hospitalizations of patients in 
large urban areas may be explained in part by the larger proportion of hospitals in the 
urban areas (urban hospitals: 2,926, rural hospitals: 2,001).49  Other possible explanations 
may include larger hospitals having more respiratory consultants, more non-physician 
specialist support, and  greater availability of wider range of services.34 
 
The mean hospital LOS per patient with COPD was found to be 4.69 days in 
2005.  Using hospital data from Spain, Iglesia et al. (2002) also reported the mean LOS to 
be 4.6 days in 2001.50   However, the mean LOS reported by this study is significantly 
lower than that reported by some other studies.  Saynajakangas et al. (2004) reported the 
mean LOS to be 6.8 days in 2001, while Kong and Bellmen (1997) found the mean LOS 
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to be 6.5 days.29, 51  A possible explanation for the significant decrease in mean LOS in 
the past few years may be due to the increasing costs of hospitalizations.52  Because of the 
increasing charges, there is a possibility that many health plans may have begun to use 
clinical practice guidelines regarding LOS to limit use of inpatient services.52  Kong and 
Bellmen (1997) also found that the necessary LOS for patients with COPD may be 
significantly less than actual LOS.  After reviewing the practice guidelines and 
conducting a retrospective study, the authors demonstrated that when patients are 
classified as low risk according to the practice guideline, the hospital LOS could 
potentially be shortened to 3.2 days, with probably little effect on quality of care.51 
 
In our study, the LOS was observed to be higher in older people (age > 64 years) 
and in females as compared to males. These results are in accordance with the findings of 
the study by Saynajakangas et al. (2004), where it was seen that the LOS was longer for 
older people and females, and the elderly females had the longest inpatient stays.29 
 
Mawajdeh et al. (1997) conducted a retrospective review of medical records of 
public and private hospitals and after controlling for all types of illness category, found 
that insured patients exhibited statistically longer hospital LOS compared to uninsured 
patients, possibly to avoid high hospital charges.53  Our study findings are consistent with 
these findings, and the LOS was observed to be shortest for uninsured patients compared 
to those with insurance coverage.  
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The LOS was found to be longer in hospitals in urban areas as compared to rural 
areas, and was longest in hospitals with large bed-sizes.  In our study, the LOS was found 
to be longest in the Northeast region and, it was shortest in the Western region. The post-
hoc analysis showed a significant difference of 1.065 days in LOS between the Northeast 
and the Western region. This is consistent with the results of a case study by Chassin 
(1983), where a similar geographic variation was reported, LOS being longest in the 
Northeast and shortest in the West.54  
 
Similar to hospital LOS, total hospital costs were found to be higher in older 
people (age > 64 years), and in females as compared to males. The possible reason for 
higher costs could be the longer LOS.  Patients with no insurance were found to have the 
least hospital costs, and this is also in accordance with results of the study by Mawajdeh, 
et al. (1997); where patients with no health insurance had substantially lower hospital 
charges than those patients with insurance.53 
 
The total hospital costs were higher for both Hispanics and African Americans, in 
comparison to Caucasians.  Most Hispanics and African Americans in our study sample 
were found to be covered by Medicare and Medicaid.  On conducting further analysis, it 
was found that, of the sample population that lacked health insurance; Hispanics 
accounted for 6%, African Americans accounted for 12%, while Caucasians accounted 
for 78%.  Further analysis also showed that African Americans had a higher average 
number of procedures listed on the discharge records, as compared to Caucasians; which 
could be suggestive of more disease severity among African Americans.  Also cross 
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tabulations showed that 52% of African Americans and 48% of Hispanics belonged to 
lowest category of the median household income groups. Studies show that African 
Americans have lower lung function than Caucasian.39  And Dransfield (2006) suggested 
that racial differences in SES may explain this difference; as poverty, a known predictor 
of lower lung function, is more common among African Americans.39   
 
Another factor, which could explain the difference in disease severity could be 
hazardous occupational exposure.  The estimated fraction of COPD cases caused by 
occupational exposure ranges from 15% to 31% among never-smokers.55  Minority 
groups have historically been overexposed to hazardous industries, and a study based on 
analysis of the National Health and Nutrition Examination Survey (NHANES) data 
showed that the fraction of airflow obstruction attributable to workplace exposure was 
lowest among Caucasians (21.5%), intermediate among African Americans (25.4%), and 
highest among Hispanics (55.7%).55  Studies have been published that address racial 
disparities in the application of smoking cessation programs, and influenza vaccination; 
both of which are interventions known to alter COPD severity.  One study reported that 
smoking cessation counseling was offered less often to African Americans than 
Caucasians (30% versus 42%), and another study showed that African American COPD 
patients were less likely than their Caucasian counterparts to receive influenza 
vaccination.39  
 
The total hospital costs in urban areas were almost twice than those for rural 
areas, and our results are in accordance with other studies which report that urban 
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location of hospitals are associated with higher hospital charges and costs.56  On 
conducting cross-tabulations, it was seen that most of the medium and the large bed-size 
hospitals were located in the urban locations.  This explains the total hospital costs being 
higher for hospitals with medium or large-bed sizes.  
The proportion of in-hospital deaths was substantially higher for those who were 
65 years and older. The proportion of in-hospital deaths were also seen to be higher in 
Caucasians, as compared to other races.  Chatila et al. (2004) examined the smoking 
habits in a group of patients with COPD and reported that for COPD- related surgeries, 
African Americans presented at an earlier age and with fewer pack-years of smoking.45   
Even in our study populations, most of the COPD patients aged 65 and above were 
Caucasian. This can explain the higher in-hospital mortality among Caucasians. However 
higher proportion of Caucasians in our study population could be a reason for these 
findings.  
 
Although males had a shorter hospital LOS, and lesser total hospital costs than 
females; the proportion of males having an in-hospital death was higher as compared to 
the proportion of females.  Further analysis showed that males had a relatively higher 
average number of procedures listed on their discharge records, as compared to females; 
indicative of disease being more severe among males.  Another possible explanation 
could be that men seek medical care, only in the later stages of the disease; usually when 
the disease is more severe, and the level of pain or discomfort is extremely high. 
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Most of the COPD related deaths were observed in those aged 65 and above, and 
this can also explain Medicare beneficiaries having substantially higher proportion of in-
hospital deaths. 
 
CONCLUSIONS OF THE STUDY 
In this study, patient- and hospital-related characteristics of COPD-related 
hospitalizations were assessed.  The study clearly demonstrated that disparities do exist in 
COPD occurrence, and the outcomes related to the disease.  The study showed that the 
burden of disease associated with COPD is substantially underestimated, and that it 
usually affects females, Caucasians, people aged 65 and above, and people from lower 
income level groups.  It was also seen that COPD most commonly affected people 
located in the metropolitan areas, and also those from the southern region of the US.  
Predictors for hospital LOS, total hospital costs, and in-hospital mortality for 
hospitalizations due to COPD were also studied.  Number of procedures and number of 
diagnoses listed on the record; were seen to be important predictors for hospital LOS, 
total hospital charges as well as in-hospital mortality.  Hospital region, gender, and payer 
were among other important predictors for hospital LOS; whereas for total hospital costs, 
important predictors included hospital region, race, and patient location. Age and gender 
were seen to be important predictors of in-hospital mortality. 
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IMPLICATIONS OF THE STUDY 
The findings of this study are important: they show that hospital resource 
utilization is high in patients with COPD, and that there are disparities in hospital 
resource utilization.  The identification of the predictors of hospital LOS, total hospital 
costs, and in-hospital mortality can be used to help the healthcare professionals in 
identifying at-risk population who would benefit most from effective management of the 
disease.  The results can also be used by policy makers to make optimal resource 
allocation decisions, such that there is equal access to care to the population at risk.  
Appropriate disease management, and application of preventative care such as early 
disease management and smoking cessation in identified population, can help in delaying 
the progression of disease, preventing exacerbations, reducing mortality; and thus help in 
lowering hospital admission rates and alleviating the economic burden of COPD. 
 
LIMITATIONS OF THE STUDY 
The present study has some limitations: the inherent limitations of a retrospective 
database are applicable to this study as well.  Some of these limitations include 
dependency on previously recorded data in the chart, whose quality may be limited by 
systematic or recorder bias, data coding-recoding errors, incomplete data, data quality, 
and confounding factors.   However, selection bias, inherent to large databases; can be 
considered negligible here due to the complex sampling frame used in designing the NIS 
database. 
Because the NIS contains hospitals discharge records from only 20% of all 
hospitals in the US, our projection of the number of COPD-related hospitalizations could 
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have been underestimated.  The NIS database did not provide any information about 
disease severity, medication use or information on other potential confounding factors 
which could affect the COPD-related outcomes such as smoking behavior, environmental 
and occupational exposure.  And the failure of considering these important confounding 
factors, in our study; is a limitation. 
NIS provides only discharge-level data, and not patient-level data. Therefore 
hospital re-admissions rates could not be determined.  Because of lack of patient 
identifiers, patients who may have been hospitalized several times for the same condition; 
could have been counted as separate individual records for analysis. As a result, the total 
cost of hospitalization for each individual patient with COPD could not be determined.  
And cost estimates for each hospitalization, as a separate event only; could be determined 
in the study. The nature of the data also led to inability to determine any  prevalence or 
incidence rates related to COPD or the other associated co morbidities. 
In NIS, the financial charge information provided is based on hospital charges and 
not on actual costs or the amounts reimbursed by the payer.  Also, several charges such as 
emergency transportation costs and physician professional fees are not included as a part 
of the hospital charges.  Thus, our estimation may not completely or accurately reflect the 
actual economic burden of COPD-related hospitalizations.  
Only 29% of the discharge records had a race/ethnicity category listed on them, 
and this could affect our results related to the racial-disparities. 
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OPPURTUNITIES FOR FUTURE RESEARCH 
Based on our study results, it is evident that disparities do exist among patients 
with COPD.  Further research needs to be conducted to better understand these 
differences, and the related factors.  
 Because co-morbidities are an important aspect of COPD, further studies should 
be conducted to determine the prevalence of the important co-morbid conditions in 
patients with COPD.  Also the differences in health outcomes and resource utilization 
should be studied across the different cohorts of patients (patient with COPD and 
different co-morbid conditions).  Results from such a study, would help develop 
treatment guidelines which would focus on early disease prevention and management of 
co-morbid conditions in patients with COPD.  Thus, providing an opportunity to avert 
additional healthcare expenditure afflicted due to the co-morbid conditions in patients 
with COPD.  COPD is now being as a systemic disorder leading to development of co-
morbid conditions.  Time-to-event or survival analysis studies could also provide an 
insight about the hazard risk ratio of developing the co-morbid conditions after being 
diagnosed with COPD. 
   Patient-level data, in the form of patient registry data or health care claims data 
with patient identifiers can be used to determine the rate of rehospitalizations and the 
identify the population at risk of rehospitalization among patients with COPD.   
Health outcomes may vary across the different therapeutic drug classes which are 
in prescribed in patients with COPD. Recent studies have shown that the beta-agonists 
prescribed in patients with COPD have been associated with an increased risk for 
cardiovascular diseases. Health care claims data with prescription drug information, 
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could be used to study the healthcare expenditure on prescription medications, and the 
differences which may exist in treatment outcomes; across the different treatment groups. 
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